News Roundup

Patients with multiple sclerosis (MS) disease activity have a higher rate of thinning of the ganglion cell/inner plexiform (GCIP) layer of the eye, researchers reported in the January 1 Neurology. Annual rates of GCIP thinning may be highest among patients with new gadolinium-enhancing lesions, new T2 lesions, and disease duration of less than five years. The investigators performed spectral-domain optical coherence tomography scans every six months on 164 patients with MS and 59 healthy controls. The mean follow-up time was 21.1 months. Annual GCIP thinning occurred 42% faster in patients with relapses, 54% faster in patients with new gadolinium-enhanced lesions, and 36% faster in patients with new T2 lesions.

Vaccination with a monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine does not appear to be associated with an increased risk of epileptic seizures, according to research published in the December 28, 2012, BMJ. Researchers studied 373,398 people with and without epilepsy who had received the vaccine. The primary end point was admission to a hospital or outpatient hospital care with epileptic seizures. The investigators found no increased risk of seizures in patients with epilepsy and a nonsignificantly decreased risk of seizures in persons without epilepsy during the initial seven-day risk period. During the subsequent 23-day risk period, people without epilepsy had a nonsignificantly increased risk of seizures, but patients with epilepsy had no increase in risk of seizures.

Variations in some genes associated with risk for psychiatric disorders may be observed as differences in brain structure in neonates, according to a study published in the January 2 online Cerebral Cortex. Investigators performed automated region-of-interest volumetry and tensor-based morphometry on 272 newborns who had had high-resolution MRI scans. The group found that estrogen receptor alpha (rs9340799) predicted intracranial volume. Polymorphisms in estrogen receptor alpha (rs9340799), as well as in disrupted-in-schizophrenia 1 (DISC1, rs821616), catechol-O-methyltransferase (COMT), neuregulin 1, apolipoprotein E, and brain-derived neurotrophic factor, were significantly associated with local variation in gray matter volume. “The results highlight the importance of prenatal brain development in mediating psychiatric risk,” noted the authors.

Four months after mild traumatic brain injury (TBI), white matter abnormalities may persist in children, even if cognitive symptoms have resolved, according to research published in the December 12, 2012, Journal of Neuroscience. The magnitude and duration of these abnormalities also appear to be greater in children with mild TBI than in adults with mild TBI. Researchers performed fractional anisotropy, axial diffusivity, and radial diffusivity on 15 children with semiacute mild TBI and 15 matched controls. Post-TBI cognitive dysfunction was observed in the domains of attention and processing speed. Increased anisotropy identified patients with pediatric mild TBI with 90% accuracy but was not associated with neuropsychologic deficits. Anisotropic diffusion may provide an objective biomarker of pediatric mild TBI.

The FDA has approved Eliquis (apixaban) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In a phase III clinical trial, Eliquis, an oral anticoagulant, reduced the risk of stroke or systemic embolism by 21%, compared with warfarin. The drug primarily reduced the risk of hemorrhagic stroke and ischemic stroke that converted to hemorrhagic stroke, and it also decreased the risks of major bleeding and all-cause mortality, compared with warfarin. Eliquis inhibits Factor Xa, a blood-clotting protein, thus decreasing thrombin generation and blood clots. The recommended dose is 5 mg twice daily. For patients age 80 or older and those who weigh 60 kg or less, the recommended dose is 2.5 mg twice daily. Eliquis is manufactured by Bristol-Myers Squibb (New York City) and comarketed with Pfizer (New York City).

Intermittent fasting, together with a ketogenic diet, may reduce seizures in children with epilepsy to a greater extent than the ketogenic diet alone, investigators reported in the November 30, 2012, online Epilepsy Research. The researchers placed six children with an incomplete response to a ketogenic diet on an intermittent fasting regimen. The children, ages 2 to 7, fasted on alternate days. Four children had transient improvement in seizure control, but they also had hunger-related adverse reactions. Three patients adhered to the combined intermittent fasting and ketogenic diet regimen for two months. The ketogenic diet and intermittent fasting may not share the same anticonvulsant mechanisms, noted the authors.

The available evidence does not support the use of cannabis extract to treat multiple sclerosis (MS), according to a review published in the December 2012 Drug and Therapeutics Bulletin. Researchers concluded that the trial data for nabiximols, a mouth spray for patients with MS containing dronabinol and cannabidiol, were limited. In the trials, which were the basis for the drug’s approval, symptoms decreased in a slightly higher number of patients taking nabiximols, compared with patients taking placebo. The drug was used for relatively short periods (ie, six weeks to four months) in many of these studies, however, and no study compared nabiximols with another active ingredient. One properly designed trial with a sufficient number of patients showed no difference in symptom relief between participants who took nabiximols and those who did not.

Baseline depression was associated with mild cognitive impairment (MCI) and dementia in individuals 65 or older, researchers reported in the December 31, 2012, Archives of Neurology. Depression may coincide with cognitive impairment, but may not precede it, the study authors noted. The investigators studied 2,160 community-dwelling Medicare recipients in New York City. The team defined depression as a score of 4 or more on the Center for Epidemiological Studies Depression scale. MCI, dementia, and progression from MCI to dementia were the study’s main outcome measures. Baseline depression was associated with an increased risk of incident dementia, but not with incident MCI. Participants with MCI and comorbid depression at baseline had a higher risk of progression to dementia, but not Alzheimer’s disease.

Consumption of fructose resulted in a smaller increase in systemic glucose, insulin, and glucagon-like polypeptide 1 levels than consumption of glucose, according to research published in the January 2 JAMA. Glucose ingestion was associated with a significantly greater reduction in hypothalamic cerebral blood flow than fructose ingestion. Researchers performed MRIs of 20 healthy adults at baseline and after ingestion of a glucose or fructose drink. The blinded study had a random-order crossover design. Compared with baseline, glucose ingestion increased functional connectivity between the hypothalamus and the thalamus and striatum. Fructose increased connectivity between the hypothalamus and thalamus, but not the striatum. Fructose reduced regional cerebral blood flow in the thalamus, hippocampus, posterior cingulate cortex, fusiform, and visual cortex.

Research published in the January 7 online Epilepsia provides evidence for a shared genetic susceptibility to epilespsy and migraine with aura. Compared with migraine without aura, the prevalence of migraine with aura was significantly increased among patients with epilepsy who have two or more first-degree relatives with epilepsy. Investigators studied the prevalence of a history of migraine in 730 participants in the Epilepsy Phenome/Genome Project. Eligible participants were 12 or older, had nonacquired focal epilepsy or generalized epilepsy, and had one or more relative epilepsy of unknown cause. The researchers collected information on migraine with and without aura using an instrument validated for individuals 12 and older. The team also interviewed participants about the history of seizure disorders in nonenrolled family members.

Higher exposure to benomyl is associated with an increased risk for Parkinson’s disease, according to an epidemiologic study published in the December 24, 2012, online Proceedings of the National Academy of Sciences. In primary mesencephalic neurons, benomyl exposure inhibits aldehyde dehydrogenase (ALDH) and alters dopamine homeostasis. Investigators tested the effects of benomyl in cell cultures and confirmed that the chemical damaged or destroyed dopaminergic neurons. The researchers also found that benomyl caused the loss of dopaminergic neurons in zebrafish. The ALDH model for Parkinson’s disease etiology may help explain the selective vulnerability of dopaminergic neurons and describe the mechanism through which environmental toxicants contribute to Parkinson’s disease pathogenesis, the authors theorized.

Patients with a history of traumatic brain injury (TBI) and loss of consciousness may have an increased risk for future TBI and loss of consciousness, according to a study published in the November 21, 2012, online Journal of Neurology, Neurosurgery, and Psychiatry. Researchers are conducting an ongoing study of 4,225 nondemented adults age 65 and older. Participants are seen every two years, and 14% have reported a lifetime history of TBI and loss of consciousness. Individuals reporting a first injury before age 25 had an adjusted hazard ratio of 2.54 for TBI and loss of consciousness, compared with a hazard ratio of 3.79 for adults with first injury after age 55.

Patients with multiple sclerosis (MS) disease activity have a higher rate of thinning of the ganglion cell/inner plexiform (GCIP) layer of the eye, researchers reported in the January 1 Neurology. Annual rates of GCIP thinning may be highest among patients with new gadolinium-enhancing lesions, new T2 lesions, and disease duration of less than five years. The investigators performed spectral-domain optical coherence tomography scans every six months on 164 patients with MS and 59 healthy controls. The mean follow-up time was 21.1 months. Annual GCIP thinning occurred 42% faster in patients with relapses, 54% faster in patients with new gadolinium-enhanced lesions, and 36% faster in patients with new T2 lesions.

Vaccination with a monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine does not appear to be associated with an increased risk of epileptic seizures, according to research published in the December 28, 2012, BMJ. Researchers studied 373,398 people with and without epilepsy who had received the vaccine. The primary end point was admission to a hospital or outpatient hospital care with epileptic seizures. The investigators found no increased risk of seizures in patients with epilepsy and a nonsignificantly decreased risk of seizures in persons without epilepsy during the initial seven-day risk period. During the subsequent 23-day risk period, people without epilepsy had a nonsignificantly increased risk of seizures, but patients with epilepsy had no increase in risk of seizures.

Variations in some genes associated with risk for psychiatric disorders may be observed as differences in brain structure in neonates, according to a study published in the January 2 online Cerebral Cortex. Investigators performed automated region-of-interest volumetry and tensor-based morphometry on 272 newborns who had had high-resolution MRI scans. The group found that estrogen receptor alpha (rs9340799) predicted intracranial volume. Polymorphisms in estrogen receptor alpha (rs9340799), as well as in disrupted-in-schizophrenia 1 (DISC1, rs821616), catechol-O-methyltransferase (COMT), neuregulin 1, apolipoprotein E, and brain-derived neurotrophic factor, were significantly associated with local variation in gray matter volume. “The results highlight the importance of prenatal brain development in mediating psychiatric risk,” noted the authors.

Four months after mild traumatic brain injury (TBI), white matter abnormalities may persist in children, even if cognitive symptoms have resolved, according to research published in the December 12, 2012, Journal of Neuroscience. The magnitude and duration of these abnormalities also appear to be greater in children with mild TBI than in adults with mild TBI. Researchers performed fractional anisotropy, axial diffusivity, and radial diffusivity on 15 children with semiacute mild TBI and 15 matched controls. Post-TBI cognitive dysfunction was observed in the domains of attention and processing speed. Increased anisotropy identified patients with pediatric mild TBI with 90% accuracy but was not associated with neuropsychologic deficits. Anisotropic diffusion may provide an objective biomarker of pediatric mild TBI.

The FDA has approved Eliquis (apixaban) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In a phase III clinical trial, Eliquis, an oral anticoagulant, reduced the risk of stroke or systemic embolism by 21%, compared with warfarin. The drug primarily reduced the risk of hemorrhagic stroke and ischemic stroke that converted to hemorrhagic stroke, and it also decreased the risks of major bleeding and all-cause mortality, compared with warfarin. Eliquis inhibits Factor Xa, a blood-clotting protein, thus decreasing thrombin generation and blood clots. The recommended dose is 5 mg twice daily. For patients age 80 or older and those who weigh 60 kg or less, the recommended dose is 2.5 mg twice daily. Eliquis is manufactured by Bristol-Myers Squibb (New York City) and comarketed with Pfizer (New York City).

Intermittent fasting, together with a ketogenic diet, may reduce seizures in children with epilepsy to a greater extent than the ketogenic diet alone, investigators reported in the November 30, 2012, online Epilepsy Research. The researchers placed six children with an incomplete response to a ketogenic diet on an intermittent fasting regimen. The children, ages 2 to 7, fasted on alternate days. Four children had transient improvement in seizure control, but they also had hunger-related adverse reactions. Three patients adhered to the combined intermittent fasting and ketogenic diet regimen for two months. The ketogenic diet and intermittent fasting may not share the same anticonvulsant mechanisms, noted the authors.

The available evidence does not support the use of cannabis extract to treat multiple sclerosis (MS), according to a review published in the December 2012 Drug and Therapeutics Bulletin. Researchers concluded that the trial data for nabiximols, a mouth spray for patients with MS containing dronabinol and cannabidiol, were limited. In the trials, which were the basis for the drug’s approval, symptoms decreased in a slightly higher number of patients taking nabiximols, compared with patients taking placebo. The drug was used for relatively short periods (ie, six weeks to four months) in many of these studies, however, and no study compared nabiximols with another active ingredient. One properly designed trial with a sufficient number of patients showed no difference in symptom relief between participants who took nabiximols and those who did not.

Baseline depression was associated with mild cognitive impairment (MCI) and dementia in individuals 65 or older, researchers reported in the December 31, 2012, Archives of Neurology. Depression may coincide with cognitive impairment, but may not precede it, the study authors noted. The investigators studied 2,160 community-dwelling Medicare recipients in New York City. The team defined depression as a score of 4 or more on the Center for Epidemiological Studies Depression scale. MCI, dementia, and progression from MCI to dementia were the study’s main outcome measures. Baseline depression was associated with an increased risk of incident dementia, but not with incident MCI. Participants with MCI and comorbid depression at baseline had a higher risk of progression to dementia, but not Alzheimer’s disease.

Consumption of fructose resulted in a smaller increase in systemic glucose, insulin, and glucagon-like polypeptide 1 levels than consumption of glucose, according to research published in the January 2 JAMA. Glucose ingestion was associated with a significantly greater reduction in hypothalamic cerebral blood flow than fructose ingestion. Researchers performed MRIs of 20 healthy adults at baseline and after ingestion of a glucose or fructose drink. The blinded study had a random-order crossover design. Compared with baseline, glucose ingestion increased functional connectivity between the hypothalamus and the thalamus and striatum. Fructose increased connectivity between the hypothalamus and thalamus, but not the striatum. Fructose reduced regional cerebral blood flow in the thalamus, hippocampus, posterior cingulate cortex, fusiform, and visual cortex.

Research published in the January 7 online Epilepsia provides evidence for a shared genetic susceptibility to epilespsy and migraine with aura. Compared with migraine without aura, the prevalence of migraine with aura was significantly increased among patients with epilepsy who have two or more first-degree relatives with epilepsy. Investigators studied the prevalence of a history of migraine in 730 participants in the Epilepsy Phenome/Genome Project. Eligible participants were 12 or older, had nonacquired focal epilepsy or generalized epilepsy, and had one or more relative epilepsy of unknown cause. The researchers collected information on migraine with and without aura using an instrument validated for individuals 12 and older. The team also interviewed participants about the history of seizure disorders in nonenrolled family members.

Higher exposure to benomyl is associated with an increased risk for Parkinson’s disease, according to an epidemiologic study published in the December 24, 2012, online Proceedings of the National Academy of Sciences. In primary mesencephalic neurons, benomyl exposure inhibits aldehyde dehydrogenase (ALDH) and alters dopamine homeostasis. Investigators tested the effects of benomyl in cell cultures and confirmed that the chemical damaged or destroyed dopaminergic neurons. The researchers also found that benomyl caused the loss of dopaminergic neurons in zebrafish. The ALDH model for Parkinson’s disease etiology may help explain the selective vulnerability of dopaminergic neurons and describe the mechanism through which environmental toxicants contribute to Parkinson’s disease pathogenesis, the authors theorized.

Patients with a history of traumatic brain injury (TBI) and loss of consciousness may have an increased risk for future TBI and loss of consciousness, according to a study published in the November 21, 2012, online Journal of Neurology, Neurosurgery, and Psychiatry. Researchers are conducting an ongoing study of 4,225 nondemented adults age 65 and older. Participants are seen every two years, and 14% have reported a lifetime history of TBI and loss of consciousness. Individuals reporting a first injury before age 25 had an adjusted hazard ratio of 2.54 for TBI and loss of consciousness, compared with a hazard ratio of 3.79 for adults with first injury after age 55.

Patients with multiple sclerosis (MS) disease activity have a higher rate of thinning of the ganglion cell/inner plexiform (GCIP) layer of the eye, researchers reported in the January 1 Neurology. Annual rates of GCIP thinning may be highest among patients with new gadolinium-enhancing lesions, new T2 lesions, and disease duration of less than five years. The investigators performed spectral-domain optical coherence tomography scans every six months on 164 patients with MS and 59 healthy controls. The mean follow-up time was 21.1 months. Annual GCIP thinning occurred 42% faster in patients with relapses, 54% faster in patients with new gadolinium-enhanced lesions, and 36% faster in patients with new T2 lesions.

Vaccination with a monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine does not appear to be associated with an increased risk of epileptic seizures, according to research published in the December 28, 2012, BMJ. Researchers studied 373,398 people with and without epilepsy who had received the vaccine. The primary end point was admission to a hospital or outpatient hospital care with epileptic seizures. The investigators found no increased risk of seizures in patients with epilepsy and a nonsignificantly decreased risk of seizures in persons without epilepsy during the initial seven-day risk period. During the subsequent 23-day risk period, people without epilepsy had a nonsignificantly increased risk of seizures, but patients with epilepsy had no increase in risk of seizures.

Variations in some genes associated with risk for psychiatric disorders may be observed as differences in brain structure in neonates, according to a study published in the January 2 online Cerebral Cortex. Investigators performed automated region-of-interest volumetry and tensor-based morphometry on 272 newborns who had had high-resolution MRI scans. The group found that estrogen receptor alpha (rs9340799) predicted intracranial volume. Polymorphisms in estrogen receptor alpha (rs9340799), as well as in disrupted-in-schizophrenia 1 (DISC1, rs821616), catechol-O-methyltransferase (COMT), neuregulin 1, apolipoprotein E, and brain-derived neurotrophic factor, were significantly associated with local variation in gray matter volume. “The results highlight the importance of prenatal brain development in mediating psychiatric risk,” noted the authors.

Four months after mild traumatic brain injury (TBI), white matter abnormalities may persist in children, even if cognitive symptoms have resolved, according to research published in the December 12, 2012, Journal of Neuroscience. The magnitude and duration of these abnormalities also appear to be greater in children with mild TBI than in adults with mild TBI. Researchers performed fractional anisotropy, axial diffusivity, and radial diffusivity on 15 children with semiacute mild TBI and 15 matched controls. Post-TBI cognitive dysfunction was observed in the domains of attention and processing speed. Increased anisotropy identified patients with pediatric mild TBI with 90% accuracy but was not associated with neuropsychologic deficits. Anisotropic diffusion may provide an objective biomarker of pediatric mild TBI.

The FDA has approved Eliquis (apixaban) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In a phase III clinical trial, Eliquis, an oral anticoagulant, reduced the risk of stroke or systemic embolism by 21%, compared with warfarin. The drug primarily reduced the risk of hemorrhagic stroke and ischemic stroke that converted to hemorrhagic stroke, and it also decreased the risks of major bleeding and all-cause mortality, compared with warfarin. Eliquis inhibits Factor Xa, a blood-clotting protein, thus decreasing thrombin generation and blood clots. The recommended dose is 5 mg twice daily. For patients age 80 or older and those who weigh 60 kg or less, the recommended dose is 2.5 mg twice daily. Eliquis is manufactured by Bristol-Myers Squibb (New York City) and comarketed with Pfizer (New York City).

Intermittent fasting, together with a ketogenic diet, may reduce seizures in children with epilepsy to a greater extent than the ketogenic diet alone, investigators reported in the November 30, 2012, online Epilepsy Research. The researchers placed six children with an incomplete response to a ketogenic diet on an intermittent fasting regimen. The children, ages 2 to 7, fasted on alternate days. Four children had transient improvement in seizure control, but they also had hunger-related adverse reactions. Three patients adhered to the combined intermittent fasting and ketogenic diet regimen for two months. The ketogenic diet and intermittent fasting may not share the same anticonvulsant mechanisms, noted the authors.

The available evidence does not support the use of cannabis extract to treat multiple sclerosis (MS), according to a review published in the December 2012 Drug and Therapeutics Bulletin. Researchers concluded that the trial data for nabiximols, a mouth spray for patients with MS containing dronabinol and cannabidiol, were limited. In the trials, which were the basis for the drug’s approval, symptoms decreased in a slightly higher number of patients taking nabiximols, compared with patients taking placebo. The drug was used for relatively short periods (ie, six weeks to four months) in many of these studies, however, and no study compared nabiximols with another active ingredient. One properly designed trial with a sufficient number of patients showed no difference in symptom relief between participants who took nabiximols and those who did not.

Baseline depression was associated with mild cognitive impairment (MCI) and dementia in individuals 65 or older, researchers reported in the December 31, 2012, Archives of Neurology. Depression may coincide with cognitive impairment, but may not precede it, the study authors noted. The investigators studied 2,160 community-dwelling Medicare recipients in New York City. The team defined depression as a score of 4 or more on the Center for Epidemiological Studies Depression scale. MCI, dementia, and progression from MCI to dementia were the study’s main outcome measures. Baseline depression was associated with an increased risk of incident dementia, but not with incident MCI. Participants with MCI and comorbid depression at baseline had a higher risk of progression to dementia, but not Alzheimer’s disease.

Consumption of fructose resulted in a smaller increase in systemic glucose, insulin, and glucagon-like polypeptide 1 levels than consumption of glucose, according to research published in the January 2 JAMA. Glucose ingestion was associated with a significantly greater reduction in hypothalamic cerebral blood flow than fructose ingestion. Researchers performed MRIs of 20 healthy adults at baseline and after ingestion of a glucose or fructose drink. The blinded study had a random-order crossover design. Compared with baseline, glucose ingestion increased functional connectivity between the hypothalamus and the thalamus and striatum. Fructose increased connectivity between the hypothalamus and thalamus, but not the striatum. Fructose reduced regional cerebral blood flow in the thalamus, hippocampus, posterior cingulate cortex, fusiform, and visual cortex.

Research published in the January 7 online Epilepsia provides evidence for a shared genetic susceptibility to epilespsy and migraine with aura. Compared with migraine without aura, the prevalence of migraine with aura was significantly increased among patients with epilepsy who have two or more first-degree relatives with epilepsy. Investigators studied the prevalence of a history of migraine in 730 participants in the Epilepsy Phenome/Genome Project. Eligible participants were 12 or older, had nonacquired focal epilepsy or generalized epilepsy, and had one or more relative epilepsy of unknown cause. The researchers collected information on migraine with and without aura using an instrument validated for individuals 12 and older. The team also interviewed participants about the history of seizure disorders in nonenrolled family members.

Higher exposure to benomyl is associated with an increased risk for Parkinson’s disease, according to an epidemiologic study published in the December 24, 2012, online Proceedings of the National Academy of Sciences. In primary mesencephalic neurons, benomyl exposure inhibits aldehyde dehydrogenase (ALDH) and alters dopamine homeostasis. Investigators tested the effects of benomyl in cell cultures and confirmed that the chemical damaged or destroyed dopaminergic neurons. The researchers also found that benomyl caused the loss of dopaminergic neurons in zebrafish. The ALDH model for Parkinson’s disease etiology may help explain the selective vulnerability of dopaminergic neurons and describe the mechanism through which environmental toxicants contribute to Parkinson’s disease pathogenesis, the authors theorized.

Patients with a history of traumatic brain injury (TBI) and loss of consciousness may have an increased risk for future TBI and loss of consciousness, according to a study published in the November 21, 2012, online Journal of Neurology, Neurosurgery, and Psychiatry. Researchers are conducting an ongoing study of 4,225 nondemented adults age 65 and older. Participants are seen every two years, and 14% have reported a lifetime history of TBI and loss of consciousness. Individuals reporting a first injury before age 25 had an adjusted hazard ratio of 2.54 for TBI and loss of consciousness, compared with a hazard ratio of 3.79 for adults with first injury after age 55.

A majority of patients with mild traumatic brain injury (mTBI) have evidence of chronic traumatic encephalopathy (CTE), according to research published in the online December 2 Brain. Of 85 participants with a history of mTBI, 68 (80%) showed postmortem evidence of the degenerative brain disease. The persons with CTE were all males ages 17 to 98, most of whom were athletes and military veterans. The researchers used a four-stage system to classify CTE, and symptoms ranged from headache and concentration difficulties in stage one to dementia, aggression, and difficulty with words in stage four. Among American football players, stage of CTE correlated with increased duration of football play, survival after football, and age of death. “There is an ordered and predictable progression of hyperphosphorylated tau abnormalities through the nervous system in CTE that occurs in conjunction with widespread axonal disruption and loss,” the researchers said.
Persons who experience traumatic brain injury (TBI) and have also been exposed to the pesticide paraquat have triple the risk of developing Parkinson’s disease, according to research published in the November 13 Neurology. From 2001 to 2011, investigators examined 357 persons with idiopathic Parkinson’s disease and 754 population controls. A validated geographic information system based on records of pesticide application was used to assess paraquat exposure, while TBI was assessed through self-report of all head injuries that involved loss of consciousness for greater than five minutes. According to the researchers, exposure to paraquat and TBI each moderately increase the risk of Parkinson’s disease. However, the risk of developing Parkinson’s disease was threefold higher in study participants with both TBI and exposure to paraquat than in participants exposed to neither risk factor, the investigators said.
Preterm-born children have a significantly reduced capacity for cortical neuroplasticity, which affects learning and memory, researchers reported in the November 14 Journal of Neuroscience. The investigators used a noninvasive magnetic brain stimulation technique to induce long-term depressionlike neuroplasticity in groups of adolescents born after early preterm, late preterm, and term gestations. “Compared with term-born adolescents, both early and late preterm adolescents had reduced long-term depressionlike neuroplasticity in response to brain stimulation that was also associated with low salivary cortisol levels,” said the study authors, adding that these findings may show a potential mechanistic link between the brain physiology of preterm birth and behavioral deficits in learning and memory. Altered hypothalamic-pituitary-adrenal axis function may modulate the altered neuroplasticity and may offer options for therapeutic interventions, the researchers concluded.
MRI scans show that patients with mild traumatic brain injury (mTBI) have abnormal default-mode network connectivity patterns, researchers reported in the December Radiology. The study used resting-state functional MRI to characterize the default-mode network and included 18 healthy controls and 23 patients with mTBI who had post-traumatic symptoms less than two months after injury. Compared with controls, patients with mTBI showed significantly reduced connectivity in the posterior cingulate complex and parietal regions, which correlated positively with neurocognitive dysfunction. Patients with mTBI also showed increased frontal connectivity around the medial prefrontal cortex, which correlated with post-traumatic symptoms such as depression, anxiety, fatigue, and postconcussion syndrome. According to the researchers, the results may “provide insight into how neuronal communication and information integration are disrupted among default-mode network key structures after mild head injury.”

Increased concentration of phosphorylated neurofilament heavy subunit (pNF-H) in the plasma, serum, and CSF of patients with amyotrophic lateral sclerosis (ALS) may be associated with faster disease progression, according to research published in the online October 31 Journal of Neurology, Neurosurgery & Psychiatry. Investigators measured pNF-H concentration in the plasma and CSF of patients with ALS from the Mayo Clinic Florida and Emory University, as well as plasma from an earlier pilot study of 20 patients with ALS. Analysis showed that higher levels of pNF-H in plasma, serum, and CSF were linked with greater decline for ALS patients. The researchers also noted that patients with bulbar onset might have higher pNF-H concentration in plasma than those with spinal onset, though the results require confirmation. “These data support further study of pNF-H in CSF, serum, and plasma as a potential ALS biomarker,” the study authors said.
Paralyzed dogs who received intraspinal transplantation of cells derived from olfactory mucosal cultures regained some movement, researchers reported in the November Brain. The investigators conducted a randomized, double-blind clinical trial in which dogs with severe chronic thoracolumbar spinal injuries received an injection of either intraspinal autologous cells derived from olfactory mucosal cultures or cell transport medium alone. Dogs who received the olfactory mucosal transplants showed significantly better fore–hind coordination than those who received only the cell transport medium. “We conclude that intraspinal olfactory mucosal cell transplantation improves communication across the damaged region of the injured spinal cord, even in chronically injured individuals. However, we find no evidence for concomitant improvement in long tract function,” the researchers said.
Suvorexant, an orexin receptor antagonist, may offer a novel approach to treating insomnia, researchers reported in the December Neurology. In a randomized, double-blind, placebo-controlled study that took place during two periods of four weeks, patients received 10 mg, 20 mg, 40 mg, or 80 mg of suvorexant in one period and placebo in the other period. Coprimary end points were sleep efficiency on night one and at the end of week four. Patients receiving suvorexant showed significant dose-related improvements on both of the primary end points compared with those receiving placebo. “Dose-related effects were also observed for sleep induction (latency to persistent sleep) and maintenance (wake after sleep onset). Suvorexant was generally well tolerated,” the researchers said.
Persons born in April have significantly more risk of developing multiple sclerosis (MS) than those born in October and November, according to research published in the online November 14 Journal of Neurology, Neurosurgery & Psychiatry. The study was a meta-analysis of previously published data on month of birth of 151,978 patients with MS. According to the researchers, the month of birth effect is “likely to be due to ultraviolet light exposure and maternal vitamin D levels.” In a separate study published in the November 20 Neurology, investigators observed an association between high levels of vitamin D in the years prior to disease onset and a decreased risk of MS. However, there was no association between gestational levels of vitamin D and MS risk in the offspring. Decreasing levels of vitamin D in the population might help explain the increase in MS cases suggested from epidemiologic studies, the study authors said.
Mutations of the immune system gene TREM2 may be linked to an increased risk of Alzheimer’s disease, researchers reported in two studies in the online November 14 New England Journal of Medicine. In one study, investigators analyzed the genetic variability in TREM2 and performed a meta-analysis on imputed data for the TREM2 variant rs75932628, which is predicted to cause a R47H substitution. The R47H mutation was highly significantly associated with Alzheimer’s disease, said the authors. In the second study, researchers examined genome sequences of 2,261 Icelanders and found that the TREM2 mutation rs75932628-T conferred a significant risk of Alzheimer’s disease (odds ratio, 2.92). “Given the reported anti-inflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer’s disease through impaired containment of inflammatory processes,” the investigators concluded.
Exposure to traffic-related air pollution during pregnancy and the first year of life is associated with autism, according to a study published in the online November Archives of General Psychiatry. Researchers conducted a population-based case-control study that included data from 279 children with autism and 245 control children with typical development. Compared with controls, those with autism were more likely to live in areas with the highest quartile of exposure to traffic-related air pollution during gestation and during the first year of life. Exposure to particulate matter and nitrogen dioxide were also linked with autism. “Further epidemiological and toxicological examinations of likely biological pathways will help determine whether these associations are causal,” the researchers concluded.
Consumption of fish and long-chain omega 3 fatty acids may moderately reduce cerebrovascular risk, but fish oil supplements may not have the same beneficial effect, according to research published in the October 30 BMJ. The systemic review and meta-analysis examined 26 prospective cohort studies and 12 randomized controlled trials with aggregate data on 794,000 participants and 34,817 cerebrovascular outcomes. Results showed that persons who ate two to four servings of fish per week and those who ate five or more servings a week had a lower risk of cerebrovascular disease, compared with persons who ate one serving a week. However, no association was observed between risk for cerebrovascular disease and long-chain omega 3 fatty acids measured as circulating biomarkers in observational studies or supplements in primary and secondary prevention trials.
Depression is the most important factor affecting the health status of patients with Parkinson’s disease, according to early findings released as part of the Parkinson’s Outcome Project, a longitudinal study examining which treatments produce the best outcomes. The study, which began in 2009, includes data from more than 5,500 patients with Parkinson’s disease. Based on this research, the National Parkinson Foundation recommends screening patients for depression at least once a year and encouraging patients to discuss any mood change with a health care professional, particularly the physician treating them for Parkinson’s disease. Patients may also benefit from bringing a family member to doctor’s appointments and asking the family member to share any changes in the patient’s mood.                          

A majority of patients with mild traumatic brain injury (mTBI) have evidence of chronic traumatic encephalopathy (CTE), according to research published in the online December 2 Brain. Of 85 participants with a history of mTBI, 68 (80%) showed postmortem evidence of the degenerative brain disease. The persons with CTE were all males ages 17 to 98, most of whom were athletes and military veterans. The researchers used a four-stage system to classify CTE, and symptoms ranged from headache and concentration difficulties in stage one to dementia, aggression, and difficulty with words in stage four. Among American football players, stage of CTE correlated with increased duration of football play, survival after football, and age of death. “There is an ordered and predictable progression of hyperphosphorylated tau abnormalities through the nervous system in CTE that occurs in conjunction with widespread axonal disruption and loss,” the researchers said.
Persons who experience traumatic brain injury (TBI) and have also been exposed to the pesticide paraquat have triple the risk of developing Parkinson’s disease, according to research published in the November 13 Neurology. From 2001 to 2011, investigators examined 357 persons with idiopathic Parkinson’s disease and 754 population controls. A validated geographic information system based on records of pesticide application was used to assess paraquat exposure, while TBI was assessed through self-report of all head injuries that involved loss of consciousness for greater than five minutes. According to the researchers, exposure to paraquat and TBI each moderately increase the risk of Parkinson’s disease. However, the risk of developing Parkinson’s disease was threefold higher in study participants with both TBI and exposure to paraquat than in participants exposed to neither risk factor, the investigators said.
Preterm-born children have a significantly reduced capacity for cortical neuroplasticity, which affects learning and memory, researchers reported in the November 14 Journal of Neuroscience. The investigators used a noninvasive magnetic brain stimulation technique to induce long-term depressionlike neuroplasticity in groups of adolescents born after early preterm, late preterm, and term gestations. “Compared with term-born adolescents, both early and late preterm adolescents had reduced long-term depressionlike neuroplasticity in response to brain stimulation that was also associated with low salivary cortisol levels,” said the study authors, adding that these findings may show a potential mechanistic link between the brain physiology of preterm birth and behavioral deficits in learning and memory. Altered hypothalamic-pituitary-adrenal axis function may modulate the altered neuroplasticity and may offer options for therapeutic interventions, the researchers concluded.
MRI scans show that patients with mild traumatic brain injury (mTBI) have abnormal default-mode network connectivity patterns, researchers reported in the December Radiology. The study used resting-state functional MRI to characterize the default-mode network and included 18 healthy controls and 23 patients with mTBI who had post-traumatic symptoms less than two months after injury. Compared with controls, patients with mTBI showed significantly reduced connectivity in the posterior cingulate complex and parietal regions, which correlated positively with neurocognitive dysfunction. Patients with mTBI also showed increased frontal connectivity around the medial prefrontal cortex, which correlated with post-traumatic symptoms such as depression, anxiety, fatigue, and postconcussion syndrome. According to the researchers, the results may “provide insight into how neuronal communication and information integration are disrupted among default-mode network key structures after mild head injury.”

Increased concentration of phosphorylated neurofilament heavy subunit (pNF-H) in the plasma, serum, and CSF of patients with amyotrophic lateral sclerosis (ALS) may be associated with faster disease progression, according to research published in the online October 31 Journal of Neurology, Neurosurgery & Psychiatry. Investigators measured pNF-H concentration in the plasma and CSF of patients with ALS from the Mayo Clinic Florida and Emory University, as well as plasma from an earlier pilot study of 20 patients with ALS. Analysis showed that higher levels of pNF-H in plasma, serum, and CSF were linked with greater decline for ALS patients. The researchers also noted that patients with bulbar onset might have higher pNF-H concentration in plasma than those with spinal onset, though the results require confirmation. “These data support further study of pNF-H in CSF, serum, and plasma as a potential ALS biomarker,” the study authors said.
Paralyzed dogs who received intraspinal transplantation of cells derived from olfactory mucosal cultures regained some movement, researchers reported in the November Brain. The investigators conducted a randomized, double-blind clinical trial in which dogs with severe chronic thoracolumbar spinal injuries received an injection of either intraspinal autologous cells derived from olfactory mucosal cultures or cell transport medium alone. Dogs who received the olfactory mucosal transplants showed significantly better fore–hind coordination than those who received only the cell transport medium. “We conclude that intraspinal olfactory mucosal cell transplantation improves communication across the damaged region of the injured spinal cord, even in chronically injured individuals. However, we find no evidence for concomitant improvement in long tract function,” the researchers said.
Suvorexant, an orexin receptor antagonist, may offer a novel approach to treating insomnia, researchers reported in the December Neurology. In a randomized, double-blind, placebo-controlled study that took place during two periods of four weeks, patients received 10 mg, 20 mg, 40 mg, or 80 mg of suvorexant in one period and placebo in the other period. Coprimary end points were sleep efficiency on night one and at the end of week four. Patients receiving suvorexant showed significant dose-related improvements on both of the primary end points compared with those receiving placebo. “Dose-related effects were also observed for sleep induction (latency to persistent sleep) and maintenance (wake after sleep onset). Suvorexant was generally well tolerated,” the researchers said.
Persons born in April have significantly more risk of developing multiple sclerosis (MS) than those born in October and November, according to research published in the online November 14 Journal of Neurology, Neurosurgery & Psychiatry. The study was a meta-analysis of previously published data on month of birth of 151,978 patients with MS. According to the researchers, the month of birth effect is “likely to be due to ultraviolet light exposure and maternal vitamin D levels.” In a separate study published in the November 20 Neurology, investigators observed an association between high levels of vitamin D in the years prior to disease onset and a decreased risk of MS. However, there was no association between gestational levels of vitamin D and MS risk in the offspring. Decreasing levels of vitamin D in the population might help explain the increase in MS cases suggested from epidemiologic studies, the study authors said.
Mutations of the immune system gene TREM2 may be linked to an increased risk of Alzheimer’s disease, researchers reported in two studies in the online November 14 New England Journal of Medicine. In one study, investigators analyzed the genetic variability in TREM2 and performed a meta-analysis on imputed data for the TREM2 variant rs75932628, which is predicted to cause a R47H substitution. The R47H mutation was highly significantly associated with Alzheimer’s disease, said the authors. In the second study, researchers examined genome sequences of 2,261 Icelanders and found that the TREM2 mutation rs75932628-T conferred a significant risk of Alzheimer’s disease (odds ratio, 2.92). “Given the reported anti-inflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer’s disease through impaired containment of inflammatory processes,” the investigators concluded.
Exposure to traffic-related air pollution during pregnancy and the first year of life is associated with autism, according to a study published in the online November Archives of General Psychiatry. Researchers conducted a population-based case-control study that included data from 279 children with autism and 245 control children with typical development. Compared with controls, those with autism were more likely to live in areas with the highest quartile of exposure to traffic-related air pollution during gestation and during the first year of life. Exposure to particulate matter and nitrogen dioxide were also linked with autism. “Further epidemiological and toxicological examinations of likely biological pathways will help determine whether these associations are causal,” the researchers concluded.
Consumption of fish and long-chain omega 3 fatty acids may moderately reduce cerebrovascular risk, but fish oil supplements may not have the same beneficial effect, according to research published in the October 30 BMJ. The systemic review and meta-analysis examined 26 prospective cohort studies and 12 randomized controlled trials with aggregate data on 794,000 participants and 34,817 cerebrovascular outcomes. Results showed that persons who ate two to four servings of fish per week and those who ate five or more servings a week had a lower risk of cerebrovascular disease, compared with persons who ate one serving a week. However, no association was observed between risk for cerebrovascular disease and long-chain omega 3 fatty acids measured as circulating biomarkers in observational studies or supplements in primary and secondary prevention trials.
Depression is the most important factor affecting the health status of patients with Parkinson’s disease, according to early findings released as part of the Parkinson’s Outcome Project, a longitudinal study examining which treatments produce the best outcomes. The study, which began in 2009, includes data from more than 5,500 patients with Parkinson’s disease. Based on this research, the National Parkinson Foundation recommends screening patients for depression at least once a year and encouraging patients to discuss any mood change with a health care professional, particularly the physician treating them for Parkinson’s disease. Patients may also benefit from bringing a family member to doctor’s appointments and asking the family member to share any changes in the patient’s mood.                          

A majority of patients with mild traumatic brain injury (mTBI) have evidence of chronic traumatic encephalopathy (CTE), according to research published in the online December 2 Brain. Of 85 participants with a history of mTBI, 68 (80%) showed postmortem evidence of the degenerative brain disease. The persons with CTE were all males ages 17 to 98, most of whom were athletes and military veterans. The researchers used a four-stage system to classify CTE, and symptoms ranged from headache and concentration difficulties in stage one to dementia, aggression, and difficulty with words in stage four. Among American football players, stage of CTE correlated with increased duration of football play, survival after football, and age of death. “There is an ordered and predictable progression of hyperphosphorylated tau abnormalities through the nervous system in CTE that occurs in conjunction with widespread axonal disruption and loss,” the researchers said.
Persons who experience traumatic brain injury (TBI) and have also been exposed to the pesticide paraquat have triple the risk of developing Parkinson’s disease, according to research published in the November 13 Neurology. From 2001 to 2011, investigators examined 357 persons with idiopathic Parkinson’s disease and 754 population controls. A validated geographic information system based on records of pesticide application was used to assess paraquat exposure, while TBI was assessed through self-report of all head injuries that involved loss of consciousness for greater than five minutes. According to the researchers, exposure to paraquat and TBI each moderately increase the risk of Parkinson’s disease. However, the risk of developing Parkinson’s disease was threefold higher in study participants with both TBI and exposure to paraquat than in participants exposed to neither risk factor, the investigators said.
Preterm-born children have a significantly reduced capacity for cortical neuroplasticity, which affects learning and memory, researchers reported in the November 14 Journal of Neuroscience. The investigators used a noninvasive magnetic brain stimulation technique to induce long-term depressionlike neuroplasticity in groups of adolescents born after early preterm, late preterm, and term gestations. “Compared with term-born adolescents, both early and late preterm adolescents had reduced long-term depressionlike neuroplasticity in response to brain stimulation that was also associated with low salivary cortisol levels,” said the study authors, adding that these findings may show a potential mechanistic link between the brain physiology of preterm birth and behavioral deficits in learning and memory. Altered hypothalamic-pituitary-adrenal axis function may modulate the altered neuroplasticity and may offer options for therapeutic interventions, the researchers concluded.
MRI scans show that patients with mild traumatic brain injury (mTBI) have abnormal default-mode network connectivity patterns, researchers reported in the December Radiology. The study used resting-state functional MRI to characterize the default-mode network and included 18 healthy controls and 23 patients with mTBI who had post-traumatic symptoms less than two months after injury. Compared with controls, patients with mTBI showed significantly reduced connectivity in the posterior cingulate complex and parietal regions, which correlated positively with neurocognitive dysfunction. Patients with mTBI also showed increased frontal connectivity around the medial prefrontal cortex, which correlated with post-traumatic symptoms such as depression, anxiety, fatigue, and postconcussion syndrome. According to the researchers, the results may “provide insight into how neuronal communication and information integration are disrupted among default-mode network key structures after mild head injury.”

Increased concentration of phosphorylated neurofilament heavy subunit (pNF-H) in the plasma, serum, and CSF of patients with amyotrophic lateral sclerosis (ALS) may be associated with faster disease progression, according to research published in the online October 31 Journal of Neurology, Neurosurgery & Psychiatry. Investigators measured pNF-H concentration in the plasma and CSF of patients with ALS from the Mayo Clinic Florida and Emory University, as well as plasma from an earlier pilot study of 20 patients with ALS. Analysis showed that higher levels of pNF-H in plasma, serum, and CSF were linked with greater decline for ALS patients. The researchers also noted that patients with bulbar onset might have higher pNF-H concentration in plasma than those with spinal onset, though the results require confirmation. “These data support further study of pNF-H in CSF, serum, and plasma as a potential ALS biomarker,” the study authors said.
Paralyzed dogs who received intraspinal transplantation of cells derived from olfactory mucosal cultures regained some movement, researchers reported in the November Brain. The investigators conducted a randomized, double-blind clinical trial in which dogs with severe chronic thoracolumbar spinal injuries received an injection of either intraspinal autologous cells derived from olfactory mucosal cultures or cell transport medium alone. Dogs who received the olfactory mucosal transplants showed significantly better fore–hind coordination than those who received only the cell transport medium. “We conclude that intraspinal olfactory mucosal cell transplantation improves communication across the damaged region of the injured spinal cord, even in chronically injured individuals. However, we find no evidence for concomitant improvement in long tract function,” the researchers said.
Suvorexant, an orexin receptor antagonist, may offer a novel approach to treating insomnia, researchers reported in the December Neurology. In a randomized, double-blind, placebo-controlled study that took place during two periods of four weeks, patients received 10 mg, 20 mg, 40 mg, or 80 mg of suvorexant in one period and placebo in the other period. Coprimary end points were sleep efficiency on night one and at the end of week four. Patients receiving suvorexant showed significant dose-related improvements on both of the primary end points compared with those receiving placebo. “Dose-related effects were also observed for sleep induction (latency to persistent sleep) and maintenance (wake after sleep onset). Suvorexant was generally well tolerated,” the researchers said.
Persons born in April have significantly more risk of developing multiple sclerosis (MS) than those born in October and November, according to research published in the online November 14 Journal of Neurology, Neurosurgery & Psychiatry. The study was a meta-analysis of previously published data on month of birth of 151,978 patients with MS. According to the researchers, the month of birth effect is “likely to be due to ultraviolet light exposure and maternal vitamin D levels.” In a separate study published in the November 20 Neurology, investigators observed an association between high levels of vitamin D in the years prior to disease onset and a decreased risk of MS. However, there was no association between gestational levels of vitamin D and MS risk in the offspring. Decreasing levels of vitamin D in the population might help explain the increase in MS cases suggested from epidemiologic studies, the study authors said.
Mutations of the immune system gene TREM2 may be linked to an increased risk of Alzheimer’s disease, researchers reported in two studies in the online November 14 New England Journal of Medicine. In one study, investigators analyzed the genetic variability in TREM2 and performed a meta-analysis on imputed data for the TREM2 variant rs75932628, which is predicted to cause a R47H substitution. The R47H mutation was highly significantly associated with Alzheimer’s disease, said the authors. In the second study, researchers examined genome sequences of 2,261 Icelanders and found that the TREM2 mutation rs75932628-T conferred a significant risk of Alzheimer’s disease (odds ratio, 2.92). “Given the reported anti-inflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer’s disease through impaired containment of inflammatory processes,” the investigators concluded.
Exposure to traffic-related air pollution during pregnancy and the first year of life is associated with autism, according to a study published in the online November Archives of General Psychiatry. Researchers conducted a population-based case-control study that included data from 279 children with autism and 245 control children with typical development. Compared with controls, those with autism were more likely to live in areas with the highest quartile of exposure to traffic-related air pollution during gestation and during the first year of life. Exposure to particulate matter and nitrogen dioxide were also linked with autism. “Further epidemiological and toxicological examinations of likely biological pathways will help determine whether these associations are causal,” the researchers concluded.
Consumption of fish and long-chain omega 3 fatty acids may moderately reduce cerebrovascular risk, but fish oil supplements may not have the same beneficial effect, according to research published in the October 30 BMJ. The systemic review and meta-analysis examined 26 prospective cohort studies and 12 randomized controlled trials with aggregate data on 794,000 participants and 34,817 cerebrovascular outcomes. Results showed that persons who ate two to four servings of fish per week and those who ate five or more servings a week had a lower risk of cerebrovascular disease, compared with persons who ate one serving a week. However, no association was observed between risk for cerebrovascular disease and long-chain omega 3 fatty acids measured as circulating biomarkers in observational studies or supplements in primary and secondary prevention trials.
Depression is the most important factor affecting the health status of patients with Parkinson’s disease, according to early findings released as part of the Parkinson’s Outcome Project, a longitudinal study examining which treatments produce the best outcomes. The study, which began in 2009, includes data from more than 5,500 patients with Parkinson’s disease. Based on this research, the National Parkinson Foundation recommends screening patients for depression at least once a year and encouraging patients to discuss any mood change with a health care professional, particularly the physician treating them for Parkinson’s disease. Patients may also benefit from bringing a family member to doctor’s appointments and asking the family member to share any changes in the patient’s mood.                          

Hormone therapy may reduce the risk of Alzheimer’s disease for women who take the treatment at a time near menopause, but if hormone therapy is begun after menopause it may not reduce such risk, according to a study in the October 30 Neurology. Researchers followed 1,768 women who were part of a population-based study and found that 176 women developed Alzheimer’s disease between 1995 and 2006. Women who used any type of hormone therapy within five years of menopause had a 30% less risk of Alzheimer’s disease. However, those who began hormone therapy five or more years after menopause did not have a reduced disease risk. In addition, women who began opposed compounds in the three years prior to the baseline assessment had an increased risk of Alzheimer’s disease. The association of hormone therapy use and risk of Alzheimer’s disease may depend on the timing of use and deserves further study, the investigators concluded.

Engaging in physical activity may protect older adults from brain atrophy and white matter lesions, researchers reported in the October 23 Neurology. The study examined self-reported leisure and physical activity at age 70 among a sample of 691 adults. At age 73, participants were assessed for structural brain biomarkers, and the investigators found that a higher level of physical activity was significantly associated with higher fractional anisotropy, less atrophy, lower white matter load, and larger gray and normal-appearing white matter volumes. These associations remained significant after adjustments for age, social class, and health status. The researchers noted that although their results support the role of physical activity as a potential neuroprotective factor, “the direction of causation is unclear from this observational study.”

Poor physical performance is associated with greater odds of dementia in persons age 90 or older, according to a study published in the online October 22 Archives of Neurology. The 629 participants (72.5% women) were from The 90+ Study, a population-based, longitudinal, epidemiologic study of aging and dementia. Participants’ mean age was 94, and all-cause dementia was the main outcome measure. Measures of physical performance included a 4-m walk, five chair stands, standing balance, and grip strength. Researchers found that poor physical performance in all measures was significantly associated with an increased risk of dementia. “Our findings suggest that dementia is a complex neurodegenerative process that may affect physical performance and cognition,” the investigators concluded. “Additional research is necessary to determine the temporal relationship between poor physical activity and cognitive dysfunction.”

Exposure to selective serotonin reuptake inhibitors (SSRI) is associated with an increased risk of intracerebral and intracranial hemorrhage, though the absolute risk of those events is low, according to a study published in the October 30 Neurology. In this meta-analysis, investigators searched for controlled observational studies that compared SSRI users with a control group not receiving SSRIs. The researchers found that intracranial and intracerebral hemorrhage were related to SSRI exposure in unadjusted and adjusted analyses. A subset of five studies showed that SSRI exposure combined with oral anticoagulants was linked with an increased risk of bleeding, compared with use of oral anticoagulants alone. “When all studies were analyzed together, increased risk was seen across cohort studies, case-control studies, and case-crossover studies,” the study authors noted.

The herpes zoster vaccine is effective in preventing herpes zoster in older adults, according to research published in the online October 17 Cochrane Database of Systematic Reviews. The study authors conducted a meta-analysis of eight randomized controlled trials of adults who had a mean age older than 60. The trials had a total of 52,269 participants. Patients who received the vaccine had fewer confirmed cases of herpes zoster than those who received placebo. Analysis of age groups showed that vaccine benefits were greatest for patients ages 60 to 69, as well as for those 70 and older. However, persons ages 60 to 69 experienced more frequent side effects than did persons 70 and older. “In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity,” wrote the researchers.

Strokes are increasingly occurring in younger patients, researchers reported in the October 23 Neurology. Between 1993 and 1994 and between 1999 and 2005, strokes were recorded in an estimated population of 1.3 million. The investigators used a mixed-model approach to test for differences in age trends over time, and they found that the mean age at stroke decreased by a significant amount, from 71.2 years in 1993/1994 to 69.2 years in 2005. Furthermore, the proportion of all strokes in persons younger than 55 increased from 12.9% in 1993 to 18.6% in 2005. “This is of great public health significance because strokes in younger patients carry the potential for greater lifetime burden of disability and because some potential contributors identified for this trend are modifiable,” the researchers concluded.

The FDA has approved perampanel (Fycompa), an AMPA receptor agonist, as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients ages 12 and older with epilepsy. Perampanel is a novel agent that reduces neuronal hyperexcitation associated with seizures by inhibiting glutamate activity at postsynaptic AMPA receptors, and it is the first antiepileptic agent approved in the US to work in this manner. In three phase III, global, randomized, double-blind, placebo-controlled studies (1,480 patients), researchers concluded that perampanel significantly reduced seizure frequency in patients with partial-onset seizures with or without secondary generalized seizures. Patients experienced adverse events that included dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder, gait disturbance, vertigo, and weight gain.

Persons who survive an ischemic stroke and continue smoking have a greater risk of heart attack, death, or another stroke, compared with those who have never smoked, researchers reported in the online October 25 Stroke. The study included 1,589 patients who experienced a first or recurrent ischemic stroke between 1996 and 1999. The investigators tracked the cohort for 10 years and found that patients who smoked when they had a stroke were 30% more likely to have a poor outcome and that current smokers who survived the first 28 days after a stroke had a 42% higher risk of poor outcome. In addition, former smokers had an 18% higher risk of poor outcomes. The authors also noted that smoking had the greatest effect on younger male patients, particularly those from a disadvantaged background.

For every 400 to 500 persons with an intermediate risk of cardiovascular disease who undergo screening for C-reactive protein or fibrinogen, one additional event in a period of 10 years may be prevented, researchers reported in the October 4 New England Journal of Medicine. In a meta-analysis of 52 prospective studies of persons without a history of cardiovascular disease, the investigators sought to determine whether assessing C-reactive protein or fibrinogen in addition to conventional cardiovascular risk factors leads to better prediction of cardiovascular risk.
Of 100,000 adults ages 40 and older, 15,025 would be classified as intermediate risk using conventional factors, and 13,199 would remain if statin therapy were initiated in accordance with guidelines. “Additional targeted assessment of C-reactive protein or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years,” the researchers stated.

Extradural motor cortex stimulation for patients with Parkinson’s disease is a safe procedure that leads to moderate improvement of motor symptoms and in quality of life, according to a study published in the October Neurosurgery. Researchers assessed the safety and efficacy of one year of unilateral extradural motor cortex stimulation in nine patients with Parkinson’s disease. At baseline, participants were evaluated with the Unified Parkinson’s Disease Rating Scale and the Parkinson’s Disease Quality of Life Questionnaire. Quality of life scores increased at months three, six, and 12, and disease scores decreased from baseline during the year. Furthermore, bilateral motor effects were observed after three to four weeks. No surgical complications, adverse events, or cognitive and behavioral changes were observed, the study authors said.

The use of beta blockers is not associated with a lower risk of composite cardiovascular events in patients with either coronary artery disease (CAD) risk factors only, known prior myocardial infarction, or known CAD without myocardial infarction, according to an investigation published in the October 3 JAMA. In this longitudinal, observational study, 44,708 patients were categorized into three cohorts— 14,043 patients with known prior myocardial infarction, 12,012 patients with known CAD but without myocardial infarction, and 18,653 patients with CAD risk factors only. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. For all outcomes tested, investigators found that event rates were not significantly different in patients with beta-blocker use, compared with those without beta-blocker use, even among those in the prior myocardial infarction cohort.

Hormone therapy may reduce the risk of Alzheimer’s disease for women who take the treatment at a time near menopause, but if hormone therapy is begun after menopause it may not reduce such risk, according to a study in the October 30 Neurology. Researchers followed 1,768 women who were part of a population-based study and found that 176 women developed Alzheimer’s disease between 1995 and 2006. Women who used any type of hormone therapy within five years of menopause had a 30% less risk of Alzheimer’s disease. However, those who began hormone therapy five or more years after menopause did not have a reduced disease risk. In addition, women who began opposed compounds in the three years prior to the baseline assessment had an increased risk of Alzheimer’s disease. The association of hormone therapy use and risk of Alzheimer’s disease may depend on the timing of use and deserves further study, the investigators concluded.

Engaging in physical activity may protect older adults from brain atrophy and white matter lesions, researchers reported in the October 23 Neurology. The study examined self-reported leisure and physical activity at age 70 among a sample of 691 adults. At age 73, participants were assessed for structural brain biomarkers, and the investigators found that a higher level of physical activity was significantly associated with higher fractional anisotropy, less atrophy, lower white matter load, and larger gray and normal-appearing white matter volumes. These associations remained significant after adjustments for age, social class, and health status. The researchers noted that although their results support the role of physical activity as a potential neuroprotective factor, “the direction of causation is unclear from this observational study.”

Poor physical performance is associated with greater odds of dementia in persons age 90 or older, according to a study published in the online October 22 Archives of Neurology. The 629 participants (72.5% women) were from The 90+ Study, a population-based, longitudinal, epidemiologic study of aging and dementia. Participants’ mean age was 94, and all-cause dementia was the main outcome measure. Measures of physical performance included a 4-m walk, five chair stands, standing balance, and grip strength. Researchers found that poor physical performance in all measures was significantly associated with an increased risk of dementia. “Our findings suggest that dementia is a complex neurodegenerative process that may affect physical performance and cognition,” the investigators concluded. “Additional research is necessary to determine the temporal relationship between poor physical activity and cognitive dysfunction.”

Exposure to selective serotonin reuptake inhibitors (SSRI) is associated with an increased risk of intracerebral and intracranial hemorrhage, though the absolute risk of those events is low, according to a study published in the October 30 Neurology. In this meta-analysis, investigators searched for controlled observational studies that compared SSRI users with a control group not receiving SSRIs. The researchers found that intracranial and intracerebral hemorrhage were related to SSRI exposure in unadjusted and adjusted analyses. A subset of five studies showed that SSRI exposure combined with oral anticoagulants was linked with an increased risk of bleeding, compared with use of oral anticoagulants alone. “When all studies were analyzed together, increased risk was seen across cohort studies, case-control studies, and case-crossover studies,” the study authors noted.

The herpes zoster vaccine is effective in preventing herpes zoster in older adults, according to research published in the online October 17 Cochrane Database of Systematic Reviews. The study authors conducted a meta-analysis of eight randomized controlled trials of adults who had a mean age older than 60. The trials had a total of 52,269 participants. Patients who received the vaccine had fewer confirmed cases of herpes zoster than those who received placebo. Analysis of age groups showed that vaccine benefits were greatest for patients ages 60 to 69, as well as for those 70 and older. However, persons ages 60 to 69 experienced more frequent side effects than did persons 70 and older. “In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity,” wrote the researchers.

Strokes are increasingly occurring in younger patients, researchers reported in the October 23 Neurology. Between 1993 and 1994 and between 1999 and 2005, strokes were recorded in an estimated population of 1.3 million. The investigators used a mixed-model approach to test for differences in age trends over time, and they found that the mean age at stroke decreased by a significant amount, from 71.2 years in 1993/1994 to 69.2 years in 2005. Furthermore, the proportion of all strokes in persons younger than 55 increased from 12.9% in 1993 to 18.6% in 2005. “This is of great public health significance because strokes in younger patients carry the potential for greater lifetime burden of disability and because some potential contributors identified for this trend are modifiable,” the researchers concluded.

The FDA has approved perampanel (Fycompa), an AMPA receptor agonist, as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients ages 12 and older with epilepsy. Perampanel is a novel agent that reduces neuronal hyperexcitation associated with seizures by inhibiting glutamate activity at postsynaptic AMPA receptors, and it is the first antiepileptic agent approved in the US to work in this manner. In three phase III, global, randomized, double-blind, placebo-controlled studies (1,480 patients), researchers concluded that perampanel significantly reduced seizure frequency in patients with partial-onset seizures with or without secondary generalized seizures. Patients experienced adverse events that included dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder, gait disturbance, vertigo, and weight gain.

Persons who survive an ischemic stroke and continue smoking have a greater risk of heart attack, death, or another stroke, compared with those who have never smoked, researchers reported in the online October 25 Stroke. The study included 1,589 patients who experienced a first or recurrent ischemic stroke between 1996 and 1999. The investigators tracked the cohort for 10 years and found that patients who smoked when they had a stroke were 30% more likely to have a poor outcome and that current smokers who survived the first 28 days after a stroke had a 42% higher risk of poor outcome. In addition, former smokers had an 18% higher risk of poor outcomes. The authors also noted that smoking had the greatest effect on younger male patients, particularly those from a disadvantaged background.

For every 400 to 500 persons with an intermediate risk of cardiovascular disease who undergo screening for C-reactive protein or fibrinogen, one additional event in a period of 10 years may be prevented, researchers reported in the October 4 New England Journal of Medicine. In a meta-analysis of 52 prospective studies of persons without a history of cardiovascular disease, the investigators sought to determine whether assessing C-reactive protein or fibrinogen in addition to conventional cardiovascular risk factors leads to better prediction of cardiovascular risk.
Of 100,000 adults ages 40 and older, 15,025 would be classified as intermediate risk using conventional factors, and 13,199 would remain if statin therapy were initiated in accordance with guidelines. “Additional targeted assessment of C-reactive protein or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years,” the researchers stated.

Extradural motor cortex stimulation for patients with Parkinson’s disease is a safe procedure that leads to moderate improvement of motor symptoms and in quality of life, according to a study published in the October Neurosurgery. Researchers assessed the safety and efficacy of one year of unilateral extradural motor cortex stimulation in nine patients with Parkinson’s disease. At baseline, participants were evaluated with the Unified Parkinson’s Disease Rating Scale and the Parkinson’s Disease Quality of Life Questionnaire. Quality of life scores increased at months three, six, and 12, and disease scores decreased from baseline during the year. Furthermore, bilateral motor effects were observed after three to four weeks. No surgical complications, adverse events, or cognitive and behavioral changes were observed, the study authors said.

The use of beta blockers is not associated with a lower risk of composite cardiovascular events in patients with either coronary artery disease (CAD) risk factors only, known prior myocardial infarction, or known CAD without myocardial infarction, according to an investigation published in the October 3 JAMA. In this longitudinal, observational study, 44,708 patients were categorized into three cohorts— 14,043 patients with known prior myocardial infarction, 12,012 patients with known CAD but without myocardial infarction, and 18,653 patients with CAD risk factors only. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. For all outcomes tested, investigators found that event rates were not significantly different in patients with beta-blocker use, compared with those without beta-blocker use, even among those in the prior myocardial infarction cohort.

Hormone therapy may reduce the risk of Alzheimer’s disease for women who take the treatment at a time near menopause, but if hormone therapy is begun after menopause it may not reduce such risk, according to a study in the October 30 Neurology. Researchers followed 1,768 women who were part of a population-based study and found that 176 women developed Alzheimer’s disease between 1995 and 2006. Women who used any type of hormone therapy within five years of menopause had a 30% less risk of Alzheimer’s disease. However, those who began hormone therapy five or more years after menopause did not have a reduced disease risk. In addition, women who began opposed compounds in the three years prior to the baseline assessment had an increased risk of Alzheimer’s disease. The association of hormone therapy use and risk of Alzheimer’s disease may depend on the timing of use and deserves further study, the investigators concluded.

Engaging in physical activity may protect older adults from brain atrophy and white matter lesions, researchers reported in the October 23 Neurology. The study examined self-reported leisure and physical activity at age 70 among a sample of 691 adults. At age 73, participants were assessed for structural brain biomarkers, and the investigators found that a higher level of physical activity was significantly associated with higher fractional anisotropy, less atrophy, lower white matter load, and larger gray and normal-appearing white matter volumes. These associations remained significant after adjustments for age, social class, and health status. The researchers noted that although their results support the role of physical activity as a potential neuroprotective factor, “the direction of causation is unclear from this observational study.”

Poor physical performance is associated with greater odds of dementia in persons age 90 or older, according to a study published in the online October 22 Archives of Neurology. The 629 participants (72.5% women) were from The 90+ Study, a population-based, longitudinal, epidemiologic study of aging and dementia. Participants’ mean age was 94, and all-cause dementia was the main outcome measure. Measures of physical performance included a 4-m walk, five chair stands, standing balance, and grip strength. Researchers found that poor physical performance in all measures was significantly associated with an increased risk of dementia. “Our findings suggest that dementia is a complex neurodegenerative process that may affect physical performance and cognition,” the investigators concluded. “Additional research is necessary to determine the temporal relationship between poor physical activity and cognitive dysfunction.”

Exposure to selective serotonin reuptake inhibitors (SSRI) is associated with an increased risk of intracerebral and intracranial hemorrhage, though the absolute risk of those events is low, according to a study published in the October 30 Neurology. In this meta-analysis, investigators searched for controlled observational studies that compared SSRI users with a control group not receiving SSRIs. The researchers found that intracranial and intracerebral hemorrhage were related to SSRI exposure in unadjusted and adjusted analyses. A subset of five studies showed that SSRI exposure combined with oral anticoagulants was linked with an increased risk of bleeding, compared with use of oral anticoagulants alone. “When all studies were analyzed together, increased risk was seen across cohort studies, case-control studies, and case-crossover studies,” the study authors noted.

The herpes zoster vaccine is effective in preventing herpes zoster in older adults, according to research published in the online October 17 Cochrane Database of Systematic Reviews. The study authors conducted a meta-analysis of eight randomized controlled trials of adults who had a mean age older than 60. The trials had a total of 52,269 participants. Patients who received the vaccine had fewer confirmed cases of herpes zoster than those who received placebo. Analysis of age groups showed that vaccine benefits were greatest for patients ages 60 to 69, as well as for those 70 and older. However, persons ages 60 to 69 experienced more frequent side effects than did persons 70 and older. “In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity,” wrote the researchers.

Strokes are increasingly occurring in younger patients, researchers reported in the October 23 Neurology. Between 1993 and 1994 and between 1999 and 2005, strokes were recorded in an estimated population of 1.3 million. The investigators used a mixed-model approach to test for differences in age trends over time, and they found that the mean age at stroke decreased by a significant amount, from 71.2 years in 1993/1994 to 69.2 years in 2005. Furthermore, the proportion of all strokes in persons younger than 55 increased from 12.9% in 1993 to 18.6% in 2005. “This is of great public health significance because strokes in younger patients carry the potential for greater lifetime burden of disability and because some potential contributors identified for this trend are modifiable,” the researchers concluded.

The FDA has approved perampanel (Fycompa), an AMPA receptor agonist, as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients ages 12 and older with epilepsy. Perampanel is a novel agent that reduces neuronal hyperexcitation associated with seizures by inhibiting glutamate activity at postsynaptic AMPA receptors, and it is the first antiepileptic agent approved in the US to work in this manner. In three phase III, global, randomized, double-blind, placebo-controlled studies (1,480 patients), researchers concluded that perampanel significantly reduced seizure frequency in patients with partial-onset seizures with or without secondary generalized seizures. Patients experienced adverse events that included dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder, gait disturbance, vertigo, and weight gain.

Persons who survive an ischemic stroke and continue smoking have a greater risk of heart attack, death, or another stroke, compared with those who have never smoked, researchers reported in the online October 25 Stroke. The study included 1,589 patients who experienced a first or recurrent ischemic stroke between 1996 and 1999. The investigators tracked the cohort for 10 years and found that patients who smoked when they had a stroke were 30% more likely to have a poor outcome and that current smokers who survived the first 28 days after a stroke had a 42% higher risk of poor outcome. In addition, former smokers had an 18% higher risk of poor outcomes. The authors also noted that smoking had the greatest effect on younger male patients, particularly those from a disadvantaged background.

For every 400 to 500 persons with an intermediate risk of cardiovascular disease who undergo screening for C-reactive protein or fibrinogen, one additional event in a period of 10 years may be prevented, researchers reported in the October 4 New England Journal of Medicine. In a meta-analysis of 52 prospective studies of persons without a history of cardiovascular disease, the investigators sought to determine whether assessing C-reactive protein or fibrinogen in addition to conventional cardiovascular risk factors leads to better prediction of cardiovascular risk.
Of 100,000 adults ages 40 and older, 15,025 would be classified as intermediate risk using conventional factors, and 13,199 would remain if statin therapy were initiated in accordance with guidelines. “Additional targeted assessment of C-reactive protein or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years,” the researchers stated.

Extradural motor cortex stimulation for patients with Parkinson’s disease is a safe procedure that leads to moderate improvement of motor symptoms and in quality of life, according to a study published in the October Neurosurgery. Researchers assessed the safety and efficacy of one year of unilateral extradural motor cortex stimulation in nine patients with Parkinson’s disease. At baseline, participants were evaluated with the Unified Parkinson’s Disease Rating Scale and the Parkinson’s Disease Quality of Life Questionnaire. Quality of life scores increased at months three, six, and 12, and disease scores decreased from baseline during the year. Furthermore, bilateral motor effects were observed after three to four weeks. No surgical complications, adverse events, or cognitive and behavioral changes were observed, the study authors said.

The use of beta blockers is not associated with a lower risk of composite cardiovascular events in patients with either coronary artery disease (CAD) risk factors only, known prior myocardial infarction, or known CAD without myocardial infarction, according to an investigation published in the October 3 JAMA. In this longitudinal, observational study, 44,708 patients were categorized into three cohorts— 14,043 patients with known prior myocardial infarction, 12,012 patients with known CAD but without myocardial infarction, and 18,653 patients with CAD risk factors only. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. For all outcomes tested, investigators found that event rates were not significantly different in patients with beta-blocker use, compared with those without beta-blocker use, even among those in the prior myocardial infarction cohort.

Transient ischemic attack (TIA) is linked with a substantial risk of disability, researchers reported in the September 13 online Stroke. The 510 consecutive patients prospectively enrolled in the study had minor stroke or TIA, were not previously disabled, and had a CT or CT angiography completed within 24 hours of symptom onset. After assessing disability 90 days following the event, the investigators found that 15% of patients had a disabled outcome. Those who experienced recurrent strokes were more likely to be disabled—53% of patients with recurrent strokes were disabled, compared with 12% of those who did not have a recurrent stroke. “In terms of absolute numbers, most patients have disability as a result of their presenting event; however, recurrent events have the largest relative impact on outcome,” the study authors concluded.
Persons with high plasma glucose levels that are still within the normal range are more likely to have atrophy of brain structures associated with neurodegenerative processes, according to a study published in the September 4 Neurology. Investigators used MRI scans to assess hippocampal and amygdalar volumes in a sample of 266 cognitively healthy persons ages 60 to 64 who did not have type 2 diabetes. Results showed that plasma glucose levels were significantly linked with hippocampal and amygdalar atrophy. After controlling for age, sex, BMI, hypertension, alcohol, and smoking, the researchers found that plasma glucose levels accounted for a 6% to 10% change in volume. “These findings suggest that even in the subclinical range and in the absence of diabetes, monitoring and management of plasma glucose levels could have an impact on cerebral health,” the study authors wrote.
The FDA has approved once-a-day tablet Aubagio (teriflunomide) for treatment of adults with relapsing forms of multiple sclerosis (MS). During a clinical trial, patients taking teriflunomide had a relapse rate that was 30% lower than that of patients taking placebo. The most common side effects observed during clinical trials were diarrhea, abnormal liver tests, nausea, and hair loss, and physicians should conduct blood tests to check patients’ liver function before the drug is prescribed as well as periodically during treatment, researchers said. In addition, because of a risk of fetal harm, women of childbearing age must have a negative pregnancy test before beginning teriflunomide and should use birth control throughout treatment. Teriflunomide is the second oral treatment therapy for MS to be approved in the United States.
Patients who appear likely to have sporadic Creutzfeldt-Jakob disease may benefit from CSF 14-3-3 assays to clarify the diagnosis, researchers reported in the online September 19 Neurology. In a systematic literature review, the investigators identified articles from 1995 to January 1, 2011, that involved patients who had CSF analysis for protein 14-3-3. Based on data from 1,849 patients, the researchers determined that assays for CSF 14-3-3 are probably moderately accurate in diagnosing Creutzfeldt-Jakob—the assays had a sensitivity of 92%, specificity of 80%, likelihood ratio of 4.7, and negative likelihood ratio of 0.10. The study authors recommend CSF 14-3-3 assays “for patients who have rapidly progressive dementia and are strongly suspected of having sporadic Creutzfeldt-Jakob and for whom diagnosis remains uncertain (pretest probably of between 20% and 90%).”
Children with migraine and children with tension-type headaches are significantly more likely to have behavioral and emotional symptoms, and the frequency of headaches affects the likelihood of these symptoms, according to a study published in the online September 17 Cephalagia. After examining a sample of 1,856 children ages 5 to 11, investigators found that those with migraine were significantly more likely to experience abnormalities in somatic, anxiety-depressive, social, attention, internalizing, and total score domains of the Child Behavior Checklist. Children with tension-type headaches had a lower rate of abnormalities than children with migraine, but those with tension-type headaches still had significantly more abnormalities than controls. Children with headaches are more likely to have internalizing symptoms than externalizing symptoms such as rule breaking and aggressivity, the researchers found.
Heavy alcohol intake is associated with experiencing intracerebral hemorrhage at a younger age, according to a study published in the September 11 Neurology. Researchers prospectively followed 562 adults with spontaneous intracerebral hemorrhage and recorded information about their alcohol intake. A total of 137 patients were heavy alcohol drinkers, and these patients were more likely to be younger (median age, 60), to have a history of ischemic heart disease, and to be smokers. Furthermore, heavy alcohol drinkers had significantly lower platelet counts and prothrombin ratio. The investigators noted that although heavy alcohol intake is associated with intracerebral hemorrhage at a younger age, “the underlying vasculopathy remains unexplored in these patients. Indirect markers suggest small-vessel disease at an early stage that might be enhanced by moderate hemostatic disorders,” the authors concluded.
Long-term use of ginkgo biloba extract does not prevent the onset of Alzheimer’s disease in older patients, according to a study published in the online September 5 Lancet Neurology. Researchers enrolled 2,854 participants in a parallel-group, double-blind clinical trial in which 1,406 persons were randomized to receive ginkgo biloba extract and 1,414 persons were randomized to placebo. After five years of follow-up, 61 participants taking ginkgo biloba were diagnosed with probable Alzheimer’s disease, while 73 participants in the placebo group received a diagnosis of probable Alzheimer’s disease, though the risk was not proportional over time. The incidence of adverse events, as well as hemorrhagic or cardiovascular events, did not differ between groups. “Long-term use of standardized ginkgo biloba extract in this trial did not reduce the risk of progression to Alzheimer’s disease compared with placebo,” the researchers concluded.
The 13.3–mg/24 h dosage strength of the Exelon Patch (rivastigmine transdermal system) has been approved by the FDA for treatment of mild to moderate Alzheimer’s disease. Approval was based on the performance of the 13.3–mg/24 h dosage in the 48-week, double-blind phase of the OPTIMA study, which analyzed patients with mild to moderate Alzheimer’s disease who met predefined functional and cognitive decline criteria for the 9.5–mg/24 h dose. Compared with patients taking the 9.5–mg/24 h dose, patients taking the 13.3–mg/24 h dose showed statistically significant improvement in overall function. In addition, the overall safety profile of the 13.3–mg/24 h dose was the same as that of the lower dose, and fewer patients on the 13.3–mg/24 h dose needed to discontinue treatment than patients on the 9.5–mg/24 h dose.

The FDA has approved Nucynta (tapentadol) for management of neuropathic pain associated with diabetic peripheral neuropathy when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. According to preclinical studies, the drug is a centrally acting synthetic analgesic, though the exact mechanism of action is unknown. In two randomized-withdrawal, placebo-controlled phase III trials, researchers studied patients who had at least a one-point reduction in pain intensity during three weeks of treatment and then continued for an additional 12 weeks on the same dose, which was titrated to balance individual tolerability and efficacy. These patients had significantly better pain control than those who switched to placebo. The most common adverse events associated with the drug were nausea, constipation, vomiting, dizziness, headache, and somnolence, but tapentadol was generally well tolerated.
A mouse model of abnormal adult-generated granule cells (DGCs) has provided the first direct evidence that abnormal DGCs are linked to seizures, researchers reported in the September 20 Neuron. To isolate the effects of the abnormal cells, investigators used a transgenic mouse model to selectively delete PTEN from DGCs generated after birth. As a result of PTEN deletion, the mammalian target of rapamycin pathway was hyperactivated, which produced abnormal DGCs that resembled those in epilepsy. “Strikingly, animals in which PTEN was deleted from 9% or more of the DGC population developed spontaneous seizures in about four weeks, confirming that abnormal DGCs, which are present in both animals and humans with epilepsy, are capable of causing the disease,” the researchers stated.
Patients with multiple sclerosis (MS) who receive gingko biloba 120 mg twice a day do not show improved cognitive performance, researchers reported in the September 18 Neurology. The investigators compared the performance of two groups of patients with MS who scored 1 SD or more below the mean on one of four neuropsychologic tests. Sixty-one patients received 120 mg of ginkgo biloba twice a day for 12 weeks, and 59 patients received placebo. The researchers evaluated participants’ cognitive performance following treatment and found no statistically significant difference in scores between the two groups. Furthermore, no significant adverse events related to gingko biloba treatment occurred, according to the study authors. Overall, the investigators concluded that gingko biloba does not improve cognitive function in patients with MS.
The Solitaire Flow Restoration device performs substantially better than the Merci Retrieval System in treating acute ischemic stroke, according to a study published in the online August 24 Lancet. In a randomized, parallel-group, noninferiority trial, the efficacy and safety of the Solitaire device, a self-expanding stent retriever designed to quickly restore blood flow, was compared with the efficacy and safety of the standard Merci Retrieval system. The 58 patients in the Solitaire group achieved the primary efficacy outcome 61% of the time, compared with 24% of patients in the Merci group, investigators said. Furthermore, patients in the Solitaire group had lower 90-day mortality than patients in the Merci group (17 versus 38). “The Solitaire device might be a future treatment of choice for endovascular recanalization in acute ischemic stroke,” the researchers concluded.          

Transient ischemic attack (TIA) is linked with a substantial risk of disability, researchers reported in the September 13 online Stroke. The 510 consecutive patients prospectively enrolled in the study had minor stroke or TIA, were not previously disabled, and had a CT or CT angiography completed within 24 hours of symptom onset. After assessing disability 90 days following the event, the investigators found that 15% of patients had a disabled outcome. Those who experienced recurrent strokes were more likely to be disabled—53% of patients with recurrent strokes were disabled, compared with 12% of those who did not have a recurrent stroke. “In terms of absolute numbers, most patients have disability as a result of their presenting event; however, recurrent events have the largest relative impact on outcome,” the study authors concluded.
Persons with high plasma glucose levels that are still within the normal range are more likely to have atrophy of brain structures associated with neurodegenerative processes, according to a study published in the September 4 Neurology. Investigators used MRI scans to assess hippocampal and amygdalar volumes in a sample of 266 cognitively healthy persons ages 60 to 64 who did not have type 2 diabetes. Results showed that plasma glucose levels were significantly linked with hippocampal and amygdalar atrophy. After controlling for age, sex, BMI, hypertension, alcohol, and smoking, the researchers found that plasma glucose levels accounted for a 6% to 10% change in volume. “These findings suggest that even in the subclinical range and in the absence of diabetes, monitoring and management of plasma glucose levels could have an impact on cerebral health,” the study authors wrote.
The FDA has approved once-a-day tablet Aubagio (teriflunomide) for treatment of adults with relapsing forms of multiple sclerosis (MS). During a clinical trial, patients taking teriflunomide had a relapse rate that was 30% lower than that of patients taking placebo. The most common side effects observed during clinical trials were diarrhea, abnormal liver tests, nausea, and hair loss, and physicians should conduct blood tests to check patients’ liver function before the drug is prescribed as well as periodically during treatment, researchers said. In addition, because of a risk of fetal harm, women of childbearing age must have a negative pregnancy test before beginning teriflunomide and should use birth control throughout treatment. Teriflunomide is the second oral treatment therapy for MS to be approved in the United States.
Patients who appear likely to have sporadic Creutzfeldt-Jakob disease may benefit from CSF 14-3-3 assays to clarify the diagnosis, researchers reported in the online September 19 Neurology. In a systematic literature review, the investigators identified articles from 1995 to January 1, 2011, that involved patients who had CSF analysis for protein 14-3-3. Based on data from 1,849 patients, the researchers determined that assays for CSF 14-3-3 are probably moderately accurate in diagnosing Creutzfeldt-Jakob—the assays had a sensitivity of 92%, specificity of 80%, likelihood ratio of 4.7, and negative likelihood ratio of 0.10. The study authors recommend CSF 14-3-3 assays “for patients who have rapidly progressive dementia and are strongly suspected of having sporadic Creutzfeldt-Jakob and for whom diagnosis remains uncertain (pretest probably of between 20% and 90%).”
Children with migraine and children with tension-type headaches are significantly more likely to have behavioral and emotional symptoms, and the frequency of headaches affects the likelihood of these symptoms, according to a study published in the online September 17 Cephalagia. After examining a sample of 1,856 children ages 5 to 11, investigators found that those with migraine were significantly more likely to experience abnormalities in somatic, anxiety-depressive, social, attention, internalizing, and total score domains of the Child Behavior Checklist. Children with tension-type headaches had a lower rate of abnormalities than children with migraine, but those with tension-type headaches still had significantly more abnormalities than controls. Children with headaches are more likely to have internalizing symptoms than externalizing symptoms such as rule breaking and aggressivity, the researchers found.
Heavy alcohol intake is associated with experiencing intracerebral hemorrhage at a younger age, according to a study published in the September 11 Neurology. Researchers prospectively followed 562 adults with spontaneous intracerebral hemorrhage and recorded information about their alcohol intake. A total of 137 patients were heavy alcohol drinkers, and these patients were more likely to be younger (median age, 60), to have a history of ischemic heart disease, and to be smokers. Furthermore, heavy alcohol drinkers had significantly lower platelet counts and prothrombin ratio. The investigators noted that although heavy alcohol intake is associated with intracerebral hemorrhage at a younger age, “the underlying vasculopathy remains unexplored in these patients. Indirect markers suggest small-vessel disease at an early stage that might be enhanced by moderate hemostatic disorders,” the authors concluded.
Long-term use of ginkgo biloba extract does not prevent the onset of Alzheimer’s disease in older patients, according to a study published in the online September 5 Lancet Neurology. Researchers enrolled 2,854 participants in a parallel-group, double-blind clinical trial in which 1,406 persons were randomized to receive ginkgo biloba extract and 1,414 persons were randomized to placebo. After five years of follow-up, 61 participants taking ginkgo biloba were diagnosed with probable Alzheimer’s disease, while 73 participants in the placebo group received a diagnosis of probable Alzheimer’s disease, though the risk was not proportional over time. The incidence of adverse events, as well as hemorrhagic or cardiovascular events, did not differ between groups. “Long-term use of standardized ginkgo biloba extract in this trial did not reduce the risk of progression to Alzheimer’s disease compared with placebo,” the researchers concluded.
The 13.3–mg/24 h dosage strength of the Exelon Patch (rivastigmine transdermal system) has been approved by the FDA for treatment of mild to moderate Alzheimer’s disease. Approval was based on the performance of the 13.3–mg/24 h dosage in the 48-week, double-blind phase of the OPTIMA study, which analyzed patients with mild to moderate Alzheimer’s disease who met predefined functional and cognitive decline criteria for the 9.5–mg/24 h dose. Compared with patients taking the 9.5–mg/24 h dose, patients taking the 13.3–mg/24 h dose showed statistically significant improvement in overall function. In addition, the overall safety profile of the 13.3–mg/24 h dose was the same as that of the lower dose, and fewer patients on the 13.3–mg/24 h dose needed to discontinue treatment than patients on the 9.5–mg/24 h dose.

The FDA has approved Nucynta (tapentadol) for management of neuropathic pain associated with diabetic peripheral neuropathy when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. According to preclinical studies, the drug is a centrally acting synthetic analgesic, though the exact mechanism of action is unknown. In two randomized-withdrawal, placebo-controlled phase III trials, researchers studied patients who had at least a one-point reduction in pain intensity during three weeks of treatment and then continued for an additional 12 weeks on the same dose, which was titrated to balance individual tolerability and efficacy. These patients had significantly better pain control than those who switched to placebo. The most common adverse events associated with the drug were nausea, constipation, vomiting, dizziness, headache, and somnolence, but tapentadol was generally well tolerated.
A mouse model of abnormal adult-generated granule cells (DGCs) has provided the first direct evidence that abnormal DGCs are linked to seizures, researchers reported in the September 20 Neuron. To isolate the effects of the abnormal cells, investigators used a transgenic mouse model to selectively delete PTEN from DGCs generated after birth. As a result of PTEN deletion, the mammalian target of rapamycin pathway was hyperactivated, which produced abnormal DGCs that resembled those in epilepsy. “Strikingly, animals in which PTEN was deleted from 9% or more of the DGC population developed spontaneous seizures in about four weeks, confirming that abnormal DGCs, which are present in both animals and humans with epilepsy, are capable of causing the disease,” the researchers stated.
Patients with multiple sclerosis (MS) who receive gingko biloba 120 mg twice a day do not show improved cognitive performance, researchers reported in the September 18 Neurology. The investigators compared the performance of two groups of patients with MS who scored 1 SD or more below the mean on one of four neuropsychologic tests. Sixty-one patients received 120 mg of ginkgo biloba twice a day for 12 weeks, and 59 patients received placebo. The researchers evaluated participants’ cognitive performance following treatment and found no statistically significant difference in scores between the two groups. Furthermore, no significant adverse events related to gingko biloba treatment occurred, according to the study authors. Overall, the investigators concluded that gingko biloba does not improve cognitive function in patients with MS.
The Solitaire Flow Restoration device performs substantially better than the Merci Retrieval System in treating acute ischemic stroke, according to a study published in the online August 24 Lancet. In a randomized, parallel-group, noninferiority trial, the efficacy and safety of the Solitaire device, a self-expanding stent retriever designed to quickly restore blood flow, was compared with the efficacy and safety of the standard Merci Retrieval system. The 58 patients in the Solitaire group achieved the primary efficacy outcome 61% of the time, compared with 24% of patients in the Merci group, investigators said. Furthermore, patients in the Solitaire group had lower 90-day mortality than patients in the Merci group (17 versus 38). “The Solitaire device might be a future treatment of choice for endovascular recanalization in acute ischemic stroke,” the researchers concluded.          

Transient ischemic attack (TIA) is linked with a substantial risk of disability, researchers reported in the September 13 online Stroke. The 510 consecutive patients prospectively enrolled in the study had minor stroke or TIA, were not previously disabled, and had a CT or CT angiography completed within 24 hours of symptom onset. After assessing disability 90 days following the event, the investigators found that 15% of patients had a disabled outcome. Those who experienced recurrent strokes were more likely to be disabled—53% of patients with recurrent strokes were disabled, compared with 12% of those who did not have a recurrent stroke. “In terms of absolute numbers, most patients have disability as a result of their presenting event; however, recurrent events have the largest relative impact on outcome,” the study authors concluded.
Persons with high plasma glucose levels that are still within the normal range are more likely to have atrophy of brain structures associated with neurodegenerative processes, according to a study published in the September 4 Neurology. Investigators used MRI scans to assess hippocampal and amygdalar volumes in a sample of 266 cognitively healthy persons ages 60 to 64 who did not have type 2 diabetes. Results showed that plasma glucose levels were significantly linked with hippocampal and amygdalar atrophy. After controlling for age, sex, BMI, hypertension, alcohol, and smoking, the researchers found that plasma glucose levels accounted for a 6% to 10% change in volume. “These findings suggest that even in the subclinical range and in the absence of diabetes, monitoring and management of plasma glucose levels could have an impact on cerebral health,” the study authors wrote.
The FDA has approved once-a-day tablet Aubagio (teriflunomide) for treatment of adults with relapsing forms of multiple sclerosis (MS). During a clinical trial, patients taking teriflunomide had a relapse rate that was 30% lower than that of patients taking placebo. The most common side effects observed during clinical trials were diarrhea, abnormal liver tests, nausea, and hair loss, and physicians should conduct blood tests to check patients’ liver function before the drug is prescribed as well as periodically during treatment, researchers said. In addition, because of a risk of fetal harm, women of childbearing age must have a negative pregnancy test before beginning teriflunomide and should use birth control throughout treatment. Teriflunomide is the second oral treatment therapy for MS to be approved in the United States.
Patients who appear likely to have sporadic Creutzfeldt-Jakob disease may benefit from CSF 14-3-3 assays to clarify the diagnosis, researchers reported in the online September 19 Neurology. In a systematic literature review, the investigators identified articles from 1995 to January 1, 2011, that involved patients who had CSF analysis for protein 14-3-3. Based on data from 1,849 patients, the researchers determined that assays for CSF 14-3-3 are probably moderately accurate in diagnosing Creutzfeldt-Jakob—the assays had a sensitivity of 92%, specificity of 80%, likelihood ratio of 4.7, and negative likelihood ratio of 0.10. The study authors recommend CSF 14-3-3 assays “for patients who have rapidly progressive dementia and are strongly suspected of having sporadic Creutzfeldt-Jakob and for whom diagnosis remains uncertain (pretest probably of between 20% and 90%).”
Children with migraine and children with tension-type headaches are significantly more likely to have behavioral and emotional symptoms, and the frequency of headaches affects the likelihood of these symptoms, according to a study published in the online September 17 Cephalagia. After examining a sample of 1,856 children ages 5 to 11, investigators found that those with migraine were significantly more likely to experience abnormalities in somatic, anxiety-depressive, social, attention, internalizing, and total score domains of the Child Behavior Checklist. Children with tension-type headaches had a lower rate of abnormalities than children with migraine, but those with tension-type headaches still had significantly more abnormalities than controls. Children with headaches are more likely to have internalizing symptoms than externalizing symptoms such as rule breaking and aggressivity, the researchers found.
Heavy alcohol intake is associated with experiencing intracerebral hemorrhage at a younger age, according to a study published in the September 11 Neurology. Researchers prospectively followed 562 adults with spontaneous intracerebral hemorrhage and recorded information about their alcohol intake. A total of 137 patients were heavy alcohol drinkers, and these patients were more likely to be younger (median age, 60), to have a history of ischemic heart disease, and to be smokers. Furthermore, heavy alcohol drinkers had significantly lower platelet counts and prothrombin ratio. The investigators noted that although heavy alcohol intake is associated with intracerebral hemorrhage at a younger age, “the underlying vasculopathy remains unexplored in these patients. Indirect markers suggest small-vessel disease at an early stage that might be enhanced by moderate hemostatic disorders,” the authors concluded.
Long-term use of ginkgo biloba extract does not prevent the onset of Alzheimer’s disease in older patients, according to a study published in the online September 5 Lancet Neurology. Researchers enrolled 2,854 participants in a parallel-group, double-blind clinical trial in which 1,406 persons were randomized to receive ginkgo biloba extract and 1,414 persons were randomized to placebo. After five years of follow-up, 61 participants taking ginkgo biloba were diagnosed with probable Alzheimer’s disease, while 73 participants in the placebo group received a diagnosis of probable Alzheimer’s disease, though the risk was not proportional over time. The incidence of adverse events, as well as hemorrhagic or cardiovascular events, did not differ between groups. “Long-term use of standardized ginkgo biloba extract in this trial did not reduce the risk of progression to Alzheimer’s disease compared with placebo,” the researchers concluded.
The 13.3–mg/24 h dosage strength of the Exelon Patch (rivastigmine transdermal system) has been approved by the FDA for treatment of mild to moderate Alzheimer’s disease. Approval was based on the performance of the 13.3–mg/24 h dosage in the 48-week, double-blind phase of the OPTIMA study, which analyzed patients with mild to moderate Alzheimer’s disease who met predefined functional and cognitive decline criteria for the 9.5–mg/24 h dose. Compared with patients taking the 9.5–mg/24 h dose, patients taking the 13.3–mg/24 h dose showed statistically significant improvement in overall function. In addition, the overall safety profile of the 13.3–mg/24 h dose was the same as that of the lower dose, and fewer patients on the 13.3–mg/24 h dose needed to discontinue treatment than patients on the 9.5–mg/24 h dose.

The FDA has approved Nucynta (tapentadol) for management of neuropathic pain associated with diabetic peripheral neuropathy when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. According to preclinical studies, the drug is a centrally acting synthetic analgesic, though the exact mechanism of action is unknown. In two randomized-withdrawal, placebo-controlled phase III trials, researchers studied patients who had at least a one-point reduction in pain intensity during three weeks of treatment and then continued for an additional 12 weeks on the same dose, which was titrated to balance individual tolerability and efficacy. These patients had significantly better pain control than those who switched to placebo. The most common adverse events associated with the drug were nausea, constipation, vomiting, dizziness, headache, and somnolence, but tapentadol was generally well tolerated.
A mouse model of abnormal adult-generated granule cells (DGCs) has provided the first direct evidence that abnormal DGCs are linked to seizures, researchers reported in the September 20 Neuron. To isolate the effects of the abnormal cells, investigators used a transgenic mouse model to selectively delete PTEN from DGCs generated after birth. As a result of PTEN deletion, the mammalian target of rapamycin pathway was hyperactivated, which produced abnormal DGCs that resembled those in epilepsy. “Strikingly, animals in which PTEN was deleted from 9% or more of the DGC population developed spontaneous seizures in about four weeks, confirming that abnormal DGCs, which are present in both animals and humans with epilepsy, are capable of causing the disease,” the researchers stated.
Patients with multiple sclerosis (MS) who receive gingko biloba 120 mg twice a day do not show improved cognitive performance, researchers reported in the September 18 Neurology. The investigators compared the performance of two groups of patients with MS who scored 1 SD or more below the mean on one of four neuropsychologic tests. Sixty-one patients received 120 mg of ginkgo biloba twice a day for 12 weeks, and 59 patients received placebo. The researchers evaluated participants’ cognitive performance following treatment and found no statistically significant difference in scores between the two groups. Furthermore, no significant adverse events related to gingko biloba treatment occurred, according to the study authors. Overall, the investigators concluded that gingko biloba does not improve cognitive function in patients with MS.
The Solitaire Flow Restoration device performs substantially better than the Merci Retrieval System in treating acute ischemic stroke, according to a study published in the online August 24 Lancet. In a randomized, parallel-group, noninferiority trial, the efficacy and safety of the Solitaire device, a self-expanding stent retriever designed to quickly restore blood flow, was compared with the efficacy and safety of the standard Merci Retrieval system. The 58 patients in the Solitaire group achieved the primary efficacy outcome 61% of the time, compared with 24% of patients in the Merci group, investigators said. Furthermore, patients in the Solitaire group had lower 90-day mortality than patients in the Merci group (17 versus 38). “The Solitaire device might be a future treatment of choice for endovascular recanalization in acute ischemic stroke,” the researchers concluded.          

Persons who are obese and who also have metabolic abnormalities are likely to have faster cognitive decline, according to a study published in the August 21 Neurology. Researchers gathered data on BMI and metabolic status at the start of the study and then administered four cognitive tests throughout the next decade. Of the 6,401 adults (ages 39 to 63) who provided data on BMI, 31% had metabolic abnormalities, which were defined as having two or more of several risk factors, including high blood pressure. In the metabolically normal group, the 10-year decline in the global cognitive score was similar among the normal weight, overweight, and obese persons. The investigators observed the fastest cognitive decline in those who were both obese and metabolically abnormal.
Patients with atrial fibrillation and chronic kidney disease have an increased risk of stroke or systemic thromboembolism and bleeding, researchers reported in the August 16 New England Journal of Medicine. The study included 132,372 patients who were discharged from the hospital with a diagnosis of nonvalvular atrial fibrillation. Among this group, 3,587 had non–end stage chronic kidney disease and 901 required
renal-replacement therapy at time of inclusion. Compared with patients who did not have renal disease, those with non–end stage chronic kidney disease and those who required renal-replacement therapy had an increased risk of stroke or systemic thromboembolism. Patients in both renal disease groups who took warfarin but not aspirin significantly decreased this risk. However, warfarin and aspirin were associated with an increased risk of bleeding, the researchers noted.
Patients with Alzheimer’s disease who are hospitalized are more likely to experience delirium, which is associated with an increased risk of cognitive decline for up to five years, researchers reported in the online August 20 Archives of Internal Medicine. The investigators prospectively collected data from 263 patients with Alzheimer’s disease between 1991 and 2006 and found that 56% of patients with Alzheimer’s disease developed delirium during hospitalization. Before hospitalization, patients showed no difference in rates of cognitive decline, but patients who developed delirium had greater cognitive deterioration in the year after hospitalization than those who did not. In addition, this increased rate of deterioration was observed throughout the five-year period following hospitalization. “Strategies to prevent delirium may represent a promising avenue to explore for ameliorating cognitive deterioration in Alzheimer’s disease,” the researchers concluded.
Chronic cerebrospinal venous insufficiency (CCSVI) does not have an impact on the neurologic function or disability progression of patients with multiple sclerosis (MS), though it does play a role in cerebral hemodynamic changes, according to a study published in the online August 21 Radiology. Using MRI, researchers assessed cerebral blood volume and flow in 39 patients with MS (25 with CCSVI), and 26 healthy controls (14 with CCSVI). Results showed that persons with CCSVI in both the MS and control groups displayed cerebral hemodynamic anomalies, but no significant relationship was observed between MS and CCSVI for any of the hemodynamic parameters. Furthermore, no correlations were found between cerebral blood flow and volume values in normal-appearing white matter or for severity of disability in patients with MS. “The data support a role of CCSVI in cerebral hemodynamic changes … regardless of the presence of MS,” the researchers concluded.
Relatives of persons who are cognitively intact during late old age and who have high levels of C-reactive protein are more likely to avoid dementia, according to a study published in the August 15 online Neurology. Researchers identified a primary sample of 1,329 patients and siblings of 277 male veteran probands who were cognitively intact and at least 75 years old. The study also included a replication sample of 202 relatives of 51 cognitively intact, community-ascertained probands who were at least 85 years old. Results from both the primary and replication samples showed that relatives with higher levels of C-reactive protein were less likely to develop dementia (hazard ratio, 0.55). “High C-reactive protein in successful cognitive aging individuals may constitute a phenotype for familial—and thus possibly genetic—successful cognitive aging,” the study authors concluded.

More cases of West Nile virus have been documented in the United States thus far in 2012 than in any year since 1999, when the disease was first detected in the US, according to the CDC. As of August 14, 700 cases of West Nile virus had been reported, and 26 people had died from the disease. The increase in cases may be a result of last year’s mild winter and this year’s wet spring, researchers theorize. Among people bitten by an infected mosquito, 20% have symptoms that last from a few days to several weeks, and approximately one in 150 of those infected with West Nile have a severe and potentially fatal illness. Severe symptoms include high fever, headache, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, vision loss, numbness, and paralysis. The neurologic effects from these severe symptoms may be permanent.

Speech therapy reorganizes the brains of patients with persistent developmental stuttering, according to a study published in the August 14 Neurology. Researchers examined resting-state functional connectivity (RSFC) and cortical thickness before and after therapy in 15 patients with stuttering who received the intervention, 13 patients with stuttering who did not receive the intervention, and 13 fluent controls. Before the therapeutic intervention, both groups of patients who stuttered had significant reductions in RSFC in the left pars opercularis as well as RSFC increases in the cerebellum. After the intervention, patients who stuttered showed decreases in stuttering and displayed RSFC levels in the cerebellum that matched those of fluent controls, though there was no change in the RSFC levels or cortical thickness of the left pars opercularis. This research suggests that the left pars opercularis and the cerebellum may play a role in stuttering, the study authors said.

Daily caffeine use provides only borderline improvement in excessive sleepiness in patients with Parkinson’s disease, but it does show benefits for motor function, researchers reported in the August 14 Neurology. In this six-week, randomized controlled clinical trial, 31 patients received placebo and 61 patients received 100 mg of caffeine supplements twice a day for three weeks, followed by 200 mg of caffeine supplements twice a day for three weeks. Analysis showed that caffeine led to a nonsignificant reduction in Epworth Sleepiness Scale score on the primary intention-to-treat analysis and a significant reduction in the Epworth Sleepiness Scale score on per-protocol analysis. In addition, use of caffeine reduced the total Unified Parkinson’s Disease Rating Scale score as well as the objective motor component. “These potential benefits suggest that a larger, long-term trial of caffeine is warranted,” the researchers concluded.

Black survivors of intracerebral hemorrhage are more likely than whites to have high blood pressure a year after stroke, which puts them at higher risk of another stroke, researchers reported in the August 16 online Stroke. The study included 162 patients (mean age, 59) with spontaneous intracerebral hemorrhage—77% of patients were black and 53% were male. At presentation, the mean arterial blood pressure in blacks was 9.6 mm Hg higher than in whites, even after adjusting for confounders. Furthermore, blacks were more likely than whites to have stage I/II hypertension one year following stroke, though there was no difference between blacks and whites at 30 days. Fewer than 20% of the overall patient group had normal blood pressure at 30 days or one year, leading researchers to conclude that “long-term blood pressure control is inadequate in patients after intracerebral hemorrhage, particularly in blacks.”                     

Persons who are obese and who also have metabolic abnormalities are likely to have faster cognitive decline, according to a study published in the August 21 Neurology. Researchers gathered data on BMI and metabolic status at the start of the study and then administered four cognitive tests throughout the next decade. Of the 6,401 adults (ages 39 to 63) who provided data on BMI, 31% had metabolic abnormalities, which were defined as having two or more of several risk factors, including high blood pressure. In the metabolically normal group, the 10-year decline in the global cognitive score was similar among the normal weight, overweight, and obese persons. The investigators observed the fastest cognitive decline in those who were both obese and metabolically abnormal.
Patients with atrial fibrillation and chronic kidney disease have an increased risk of stroke or systemic thromboembolism and bleeding, researchers reported in the August 16 New England Journal of Medicine. The study included 132,372 patients who were discharged from the hospital with a diagnosis of nonvalvular atrial fibrillation. Among this group, 3,587 had non–end stage chronic kidney disease and 901 required
renal-replacement therapy at time of inclusion. Compared with patients who did not have renal disease, those with non–end stage chronic kidney disease and those who required renal-replacement therapy had an increased risk of stroke or systemic thromboembolism. Patients in both renal disease groups who took warfarin but not aspirin significantly decreased this risk. However, warfarin and aspirin were associated with an increased risk of bleeding, the researchers noted.
Patients with Alzheimer’s disease who are hospitalized are more likely to experience delirium, which is associated with an increased risk of cognitive decline for up to five years, researchers reported in the online August 20 Archives of Internal Medicine. The investigators prospectively collected data from 263 patients with Alzheimer’s disease between 1991 and 2006 and found that 56% of patients with Alzheimer’s disease developed delirium during hospitalization. Before hospitalization, patients showed no difference in rates of cognitive decline, but patients who developed delirium had greater cognitive deterioration in the year after hospitalization than those who did not. In addition, this increased rate of deterioration was observed throughout the five-year period following hospitalization. “Strategies to prevent delirium may represent a promising avenue to explore for ameliorating cognitive deterioration in Alzheimer’s disease,” the researchers concluded.
Chronic cerebrospinal venous insufficiency (CCSVI) does not have an impact on the neurologic function or disability progression of patients with multiple sclerosis (MS), though it does play a role in cerebral hemodynamic changes, according to a study published in the online August 21 Radiology. Using MRI, researchers assessed cerebral blood volume and flow in 39 patients with MS (25 with CCSVI), and 26 healthy controls (14 with CCSVI). Results showed that persons with CCSVI in both the MS and control groups displayed cerebral hemodynamic anomalies, but no significant relationship was observed between MS and CCSVI for any of the hemodynamic parameters. Furthermore, no correlations were found between cerebral blood flow and volume values in normal-appearing white matter or for severity of disability in patients with MS. “The data support a role of CCSVI in cerebral hemodynamic changes … regardless of the presence of MS,” the researchers concluded.
Relatives of persons who are cognitively intact during late old age and who have high levels of C-reactive protein are more likely to avoid dementia, according to a study published in the August 15 online Neurology. Researchers identified a primary sample of 1,329 patients and siblings of 277 male veteran probands who were cognitively intact and at least 75 years old. The study also included a replication sample of 202 relatives of 51 cognitively intact, community-ascertained probands who were at least 85 years old. Results from both the primary and replication samples showed that relatives with higher levels of C-reactive protein were less likely to develop dementia (hazard ratio, 0.55). “High C-reactive protein in successful cognitive aging individuals may constitute a phenotype for familial—and thus possibly genetic—successful cognitive aging,” the study authors concluded.

More cases of West Nile virus have been documented in the United States thus far in 2012 than in any year since 1999, when the disease was first detected in the US, according to the CDC. As of August 14, 700 cases of West Nile virus had been reported, and 26 people had died from the disease. The increase in cases may be a result of last year’s mild winter and this year’s wet spring, researchers theorize. Among people bitten by an infected mosquito, 20% have symptoms that last from a few days to several weeks, and approximately one in 150 of those infected with West Nile have a severe and potentially fatal illness. Severe symptoms include high fever, headache, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, vision loss, numbness, and paralysis. The neurologic effects from these severe symptoms may be permanent.

Speech therapy reorganizes the brains of patients with persistent developmental stuttering, according to a study published in the August 14 Neurology. Researchers examined resting-state functional connectivity (RSFC) and cortical thickness before and after therapy in 15 patients with stuttering who received the intervention, 13 patients with stuttering who did not receive the intervention, and 13 fluent controls. Before the therapeutic intervention, both groups of patients who stuttered had significant reductions in RSFC in the left pars opercularis as well as RSFC increases in the cerebellum. After the intervention, patients who stuttered showed decreases in stuttering and displayed RSFC levels in the cerebellum that matched those of fluent controls, though there was no change in the RSFC levels or cortical thickness of the left pars opercularis. This research suggests that the left pars opercularis and the cerebellum may play a role in stuttering, the study authors said.

Daily caffeine use provides only borderline improvement in excessive sleepiness in patients with Parkinson’s disease, but it does show benefits for motor function, researchers reported in the August 14 Neurology. In this six-week, randomized controlled clinical trial, 31 patients received placebo and 61 patients received 100 mg of caffeine supplements twice a day for three weeks, followed by 200 mg of caffeine supplements twice a day for three weeks. Analysis showed that caffeine led to a nonsignificant reduction in Epworth Sleepiness Scale score on the primary intention-to-treat analysis and a significant reduction in the Epworth Sleepiness Scale score on per-protocol analysis. In addition, use of caffeine reduced the total Unified Parkinson’s Disease Rating Scale score as well as the objective motor component. “These potential benefits suggest that a larger, long-term trial of caffeine is warranted,” the researchers concluded.

Black survivors of intracerebral hemorrhage are more likely than whites to have high blood pressure a year after stroke, which puts them at higher risk of another stroke, researchers reported in the August 16 online Stroke. The study included 162 patients (mean age, 59) with spontaneous intracerebral hemorrhage—77% of patients were black and 53% were male. At presentation, the mean arterial blood pressure in blacks was 9.6 mm Hg higher than in whites, even after adjusting for confounders. Furthermore, blacks were more likely than whites to have stage I/II hypertension one year following stroke, though there was no difference between blacks and whites at 30 days. Fewer than 20% of the overall patient group had normal blood pressure at 30 days or one year, leading researchers to conclude that “long-term blood pressure control is inadequate in patients after intracerebral hemorrhage, particularly in blacks.”                     

Persons who are obese and who also have metabolic abnormalities are likely to have faster cognitive decline, according to a study published in the August 21 Neurology. Researchers gathered data on BMI and metabolic status at the start of the study and then administered four cognitive tests throughout the next decade. Of the 6,401 adults (ages 39 to 63) who provided data on BMI, 31% had metabolic abnormalities, which were defined as having two or more of several risk factors, including high blood pressure. In the metabolically normal group, the 10-year decline in the global cognitive score was similar among the normal weight, overweight, and obese persons. The investigators observed the fastest cognitive decline in those who were both obese and metabolically abnormal.
Patients with atrial fibrillation and chronic kidney disease have an increased risk of stroke or systemic thromboembolism and bleeding, researchers reported in the August 16 New England Journal of Medicine. The study included 132,372 patients who were discharged from the hospital with a diagnosis of nonvalvular atrial fibrillation. Among this group, 3,587 had non–end stage chronic kidney disease and 901 required
renal-replacement therapy at time of inclusion. Compared with patients who did not have renal disease, those with non–end stage chronic kidney disease and those who required renal-replacement therapy had an increased risk of stroke or systemic thromboembolism. Patients in both renal disease groups who took warfarin but not aspirin significantly decreased this risk. However, warfarin and aspirin were associated with an increased risk of bleeding, the researchers noted.
Patients with Alzheimer’s disease who are hospitalized are more likely to experience delirium, which is associated with an increased risk of cognitive decline for up to five years, researchers reported in the online August 20 Archives of Internal Medicine. The investigators prospectively collected data from 263 patients with Alzheimer’s disease between 1991 and 2006 and found that 56% of patients with Alzheimer’s disease developed delirium during hospitalization. Before hospitalization, patients showed no difference in rates of cognitive decline, but patients who developed delirium had greater cognitive deterioration in the year after hospitalization than those who did not. In addition, this increased rate of deterioration was observed throughout the five-year period following hospitalization. “Strategies to prevent delirium may represent a promising avenue to explore for ameliorating cognitive deterioration in Alzheimer’s disease,” the researchers concluded.
Chronic cerebrospinal venous insufficiency (CCSVI) does not have an impact on the neurologic function or disability progression of patients with multiple sclerosis (MS), though it does play a role in cerebral hemodynamic changes, according to a study published in the online August 21 Radiology. Using MRI, researchers assessed cerebral blood volume and flow in 39 patients with MS (25 with CCSVI), and 26 healthy controls (14 with CCSVI). Results showed that persons with CCSVI in both the MS and control groups displayed cerebral hemodynamic anomalies, but no significant relationship was observed between MS and CCSVI for any of the hemodynamic parameters. Furthermore, no correlations were found between cerebral blood flow and volume values in normal-appearing white matter or for severity of disability in patients with MS. “The data support a role of CCSVI in cerebral hemodynamic changes … regardless of the presence of MS,” the researchers concluded.
Relatives of persons who are cognitively intact during late old age and who have high levels of C-reactive protein are more likely to avoid dementia, according to a study published in the August 15 online Neurology. Researchers identified a primary sample of 1,329 patients and siblings of 277 male veteran probands who were cognitively intact and at least 75 years old. The study also included a replication sample of 202 relatives of 51 cognitively intact, community-ascertained probands who were at least 85 years old. Results from both the primary and replication samples showed that relatives with higher levels of C-reactive protein were less likely to develop dementia (hazard ratio, 0.55). “High C-reactive protein in successful cognitive aging individuals may constitute a phenotype for familial—and thus possibly genetic—successful cognitive aging,” the study authors concluded.

More cases of West Nile virus have been documented in the United States thus far in 2012 than in any year since 1999, when the disease was first detected in the US, according to the CDC. As of August 14, 700 cases of West Nile virus had been reported, and 26 people had died from the disease. The increase in cases may be a result of last year’s mild winter and this year’s wet spring, researchers theorize. Among people bitten by an infected mosquito, 20% have symptoms that last from a few days to several weeks, and approximately one in 150 of those infected with West Nile have a severe and potentially fatal illness. Severe symptoms include high fever, headache, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, vision loss, numbness, and paralysis. The neurologic effects from these severe symptoms may be permanent.

Speech therapy reorganizes the brains of patients with persistent developmental stuttering, according to a study published in the August 14 Neurology. Researchers examined resting-state functional connectivity (RSFC) and cortical thickness before and after therapy in 15 patients with stuttering who received the intervention, 13 patients with stuttering who did not receive the intervention, and 13 fluent controls. Before the therapeutic intervention, both groups of patients who stuttered had significant reductions in RSFC in the left pars opercularis as well as RSFC increases in the cerebellum. After the intervention, patients who stuttered showed decreases in stuttering and displayed RSFC levels in the cerebellum that matched those of fluent controls, though there was no change in the RSFC levels or cortical thickness of the left pars opercularis. This research suggests that the left pars opercularis and the cerebellum may play a role in stuttering, the study authors said.

Daily caffeine use provides only borderline improvement in excessive sleepiness in patients with Parkinson’s disease, but it does show benefits for motor function, researchers reported in the August 14 Neurology. In this six-week, randomized controlled clinical trial, 31 patients received placebo and 61 patients received 100 mg of caffeine supplements twice a day for three weeks, followed by 200 mg of caffeine supplements twice a day for three weeks. Analysis showed that caffeine led to a nonsignificant reduction in Epworth Sleepiness Scale score on the primary intention-to-treat analysis and a significant reduction in the Epworth Sleepiness Scale score on per-protocol analysis. In addition, use of caffeine reduced the total Unified Parkinson’s Disease Rating Scale score as well as the objective motor component. “These potential benefits suggest that a larger, long-term trial of caffeine is warranted,” the researchers concluded.

Black survivors of intracerebral hemorrhage are more likely than whites to have high blood pressure a year after stroke, which puts them at higher risk of another stroke, researchers reported in the August 16 online Stroke. The study included 162 patients (mean age, 59) with spontaneous intracerebral hemorrhage—77% of patients were black and 53% were male. At presentation, the mean arterial blood pressure in blacks was 9.6 mm Hg higher than in whites, even after adjusting for confounders. Furthermore, blacks were more likely than whites to have stage I/II hypertension one year following stroke, though there was no difference between blacks and whites at 30 days. Fewer than 20% of the overall patient group had normal blood pressure at 30 days or one year, leading researchers to conclude that “long-term blood pressure control is inadequate in patients after intracerebral hemorrhage, particularly in blacks.”